beta-alanine has been researched along with dabigatran in 1006 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1005 (99.90) | 24.3611 |
| 2020's | 1 (0.10) | 2.80 |
| Authors | Studies |
|---|---|
| Gogarten, W; Pauschert, R; Quante, M | 1 |
| Christersson, C; Johnell, M; Siegbahn, A | 1 |
| Díaz-Cremades, JM; Fernández-Fuertes, F; Ruano, JA | 1 |
| Ebner, T; Wagner, K; Wienen, W | 1 |
| Adiguzel, C; Walenga, JM | 1 |
| Daskalopoulos, ME; Karangelis, D; Tagarakis, GI; Tsilimingas, NB | 1 |
| Barrios, V; Escobar, C; Jimenez, D | 1 |
| Hoylaerts, MF; Peetermans, WE; Vanassche, T; Verhaegen, J; Verhamme, P | 1 |
| Douketis, JD | 2 |
| Ageno, W; Rancan, E; Romualdi, E; Siragusa, S | 1 |
| Jamil-Copley, S; Kanagaratnam, P | 1 |
| Brouns, R; De Keyser, J; De Raedt, S; De Smedt, A; Nieboer, K | 1 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Broukhim, M; Halperin, JL | 1 |
| Gil Núñez, A | 2 |
| Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Morris, TA | 1 |
| Michota, F | 1 |
| Messinger-Rapport, B | 1 |
| Cucurull i Canosa, J; Escoda García, M; Just Sarobe, M; Vega-Molpeceres, S | 1 |
| Baghaei, F; Blixter, IF; Gustafsson, KM; Hillarp, A; Lindahl, TL; Sten-Linder, M; Stigendal, L; Strandberg, K | 1 |
| Oliver, M | 1 |
| Abdollah, H; Baranchuk, AM; Michael, KA; Miranda, RI; Redfearn, DP; Simpson, CS | 1 |
| Kwok, CS; Loke, YK | 1 |
| Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Hantel, S; Hermansson, K; Huo, MH; Kurth, AA; Schnee, JM | 1 |
| Ahrens, I; Lip, GY; Peter, K | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| DeDea, L | 2 |
| Connolly, SJ | 1 |
| Akter, T; Bogatkevich, GS; Ludwicka-Bradley, A; Nietert, PJ; Silver, RM; van Ryn, J | 1 |
| Faltas, B | 1 |
| Albert, N; Anderson, JL; Cannom, DS; Creager, MA; Crijns, HJ; Curtis, AB; Ellenbogen, KA; Estes, NA; Ettinger, SM; Ezekowitz, MD; Fuster, V; Guyton, RA; Halperin, JL; Hochman, JS; Jackman, WM; Jacobs, AK; January, CT; Kay, GN; Kushner, FG; Le Heuzey, JY; Lowe, JE; Ohman, EM; Olsson, SB; Page, RL; Prystowsky, EN; Rydén, LE; Slotwiner, DJ; Stevenson, WG; Tamargo, JL; Tracy, CM; Wann, LS; Yancy, CW | 2 |
| Curtis, AB; Ellenbogen, KA; Estes, NA; Ezekowitz, MD; Jackman, WM; January, CT; Lowe, JE; Page, RL; Slotwiner, DJ; Stevenson, WG; Tracy, CM; Wann, LS | 1 |
| Ageno, W; Prandoni, P | 1 |
| Calvo Romero, JM | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Beyer-Westendorf, J; Folprecht, G; Weiss, N; Werth, S | 1 |
| Samama, CM | 1 |
| Ageno, W; Streif, W | 1 |
| Kirsch, B | 1 |
| Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Uchiyama, S | 2 |
| Gums, JG | 1 |
| Beasley, BN; Temple, R; Unger, EF | 1 |
| Edwards, DB; Silverberg, J | 1 |
| Berg, AM | 1 |
| Alonso de Leciñana, M; Aparicio, M; Buisan, J; García-Caldentey, J; Guillán, M; Masjuan, J; Matute, MC | 1 |
| Yamashita, T | 1 |
| Cannon, CP; Stecker, EC | 1 |
| Fisher, WD | 1 |
| Nutescu, E | 1 |
| Baker, WL; Bendel, SD; Bona, R | 1 |
| Dobrev, D | 1 |
| Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L | 1 |
| Bode, C; Moser, M | 2 |
| Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Majeed, A; Schulman, S | 3 |
| Huisman, MV; Kooiman, J; van de Peppel, WR; van der Meer, FJ | 1 |
| Khanna, V; Reynolds, M; Reynolds, MR; Rutzen-Lopez, H; Vkhanna, V | 1 |
| Gage, BF; Shah, SV | 1 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Fareed, J; Hull, R; Welzel, D | 1 |
| Arnaout, S; Musallam, KM; Rabah, A; Sawaya, FJ; Sawaya, J | 1 |
| DeRemer, CE; Gujral, JS; Sorrentino, RA; Thornton, JW | 1 |
| Keltai, K; Keltai, M | 1 |
| Batjer, HH; Bendok, BR; Bernstein, R; Rahme, RJ | 1 |
| Aizawa, Y; Atarashi, H; Inoue, H; Kamakura, S; Koretsune, Y; Kumagai, K; Mitamura, H; Ogawa, S; Okumura, K; Sugi, K; Yamashita, T; Yasaka, M | 1 |
| Fuster, V; Halperin, JL; Viles-Gonzalez, JF | 1 |
| Lee, TH | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 2 |
| Baruch, L; Sherman, O | 1 |
| Ezekowitz, MD; Nagarakanti, R | 1 |
| Aikens, TH; Ezekowitz, MD; Nagarakanti, R; Shapiro, T | 1 |
| Kazmi, RS; Lwaleed, BA | 1 |
| Gage, L | 1 |
| Eckardt, L; Shin, DI | 1 |
| Stiefelhagen, P | 3 |
| del Zoppo, GJ; Eliasziw, M | 1 |
| Asmis, LM | 1 |
| Ganjehei, L; Massumi, A; Rasekh, A; Razavi, M | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Fauchier, L; Le Heuzey, JY; Marijon, E | 1 |
| Kavanagh, EC; Lawler, L; Murphy, L | 1 |
| Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
| Mega, JL | 1 |
| Averkov, OV | 1 |
| Blais, DM; Boyd, JM; Hummel, J; Whitehead, H | 1 |
| Mousa, SA | 1 |
| Babu, KM; Boyer, EW; Brown, RS; Ganetsky, M; Salhanick, SD | 1 |
| Di Pasquale, G; Riva, L | 1 |
| Buller, HR; Eerenberg, ES; Kamphuisen, PW; Levi, M; Meijers, JC; Sijpkens, MK | 1 |
| Pernod, G | 1 |
| Beer, JH | 1 |
| Hunchuck, JE; Lake, JD | 1 |
| Astell, H; Stewart, RA; White, HD; Young, L | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Galanis, T; Kraft, WK; Merli, GJ | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 2 |
| Friedman, RJ | 1 |
| Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A | 1 |
| Hariharan, S; Madabushi, R | 1 |
| Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C | 1 |
| Bartholomew, JR; Wartak, SA | 1 |
| Battinelli, EM | 1 |
| Bode, C; Diener, HC; Kaeufer, T | 1 |
| Henry, DM | 1 |
| Augoustides, JG | 1 |
| Kowey, PR | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Basset, T; Delavenne, X; Laporte, S; Mismetti, P; Moracchini, J | 1 |
| Banerjee, A; Lip, GY; Marín, F | 1 |
| Bendszus, M; Heiland, S; Illanes, S; Liesz, A; Middelhoff, M; Schwarting, S; van Ryn, J; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Nagatani, K; Nawashiro, H; Osada, H; Otani, N; Takeuchi, S; Wada, K | 1 |
| Cheng, A; Hoylaerts, MF; Peetermans, WE; Schneewind, O; VAN Ryn, J; Vanassche, T; Verhaegen, J; Verhamme, P | 1 |
| Fürll, B; Greinacher, A; Hackbarth, C; Krauel, K | 1 |
| Jolobe, OM | 1 |
| Yates, SW | 1 |
| Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Beyth, RJ; Landefeld, CS | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N | 1 |
| Golembiewski, JA | 1 |
| Al-Khatib, SM; Alexander, JH; Granger, CB; Lopes, RD; Mahaffey, KW; Patel, MR | 1 |
| Cotton, BA; Holcomb, JB; McCarthy, JJ | 1 |
| Panchenko, EP | 1 |
| Garwood, CL; Hwang, JM; Moser, LR | 1 |
| Finsterer, J; Stöllberger, C | 3 |
| Calle Escobar, ML; Casado Naranjo, I; Jiménez Caballero, PE; Portilla-Cuenca, JC; Romero Sevilla, RM | 1 |
| Dempfle, CE; Hennerici, MG | 1 |
| Diener, HC; Hohnloser, SH; Lip, GY; Weber, R | 1 |
| Deloughery, TG; Liem, TK | 1 |
| Alberts, MJ; Bernstein, RA; Garcia, DA; Naccarelli, GV | 1 |
| Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM | 1 |
| Büller, HR; Combe, S | 1 |
| Asakura, H | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Barez, A; Martínez, MP; Navarro-Dorado, J; Ramajo, M; Redondo, S; Tejerina, T | 1 |
| Boniface, K; Moore, CH; Scott, J; Snashall, J | 1 |
| Fieland, D; Taylor, M | 1 |
| Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, J; Ezekowitz, M; Hohnloser, SH; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Freuler, M; Pezzotti, W | 1 |
| Feuring, M; Stangier, J | 1 |
| Redberg, RF | 2 |
| Jacobs, JM; Stessman, J | 1 |
| Hernandez, AV; Uchino, K | 1 |
| Chitolie, A; Green, L; Haddad, FS; Lawrie, AS; Machin, SJ; Mackie, IJ; Patel, R; Stephens, RC | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Engh, JA; Parry, PV | 1 |
| Diener, HC; Eikelboom, J; Granger, CB; Hacke, W | 1 |
| Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ | 1 |
| Mullard, A | 1 |
| Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Knight, BP | 1 |
| Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR | 1 |
| Baruch, L; Clemens, A; van Ryn, J | 1 |
| Easton, JD; Johnston, SC; Kamel, H; Kim, AS | 1 |
| Godier, A; Lakhdari, M; Martin, AC; Samama, CM | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Giese, C; Harenberg, J; Krämer, R; Marx, S | 1 |
| Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ | 1 |
| Goldhaber, SZ | 1 |
| Dahl, OE | 1 |
| Goto, S | 1 |
| Abraham, ME; Marcy, TR | 1 |
| Alpert, JS | 1 |
| Comin, J; Kallmes, DF | 1 |
| Soff, GA | 1 |
| Curley, H; Denaro, C | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Quinlan, DJ; Yusuf, S | 1 |
| Brueckmann, M; Connolly, S; Ezekowitz, M; Flaker, G; Hohnloser, SH; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
| Masjuan, J | 3 |
| Calleja-Puerta, S | 1 |
| Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM | 1 |
| Mahan, C; Spyropoulos, AC | 1 |
| Harper, P; Merriman, E; Young, L | 1 |
| Abdelhafiz, AH; Ali, A; Bailey, C | 1 |
| Connolly, SJ; Eikelboom, JW; Lamy, A; Margetts, P; Ricci, C; Warkentin, TE | 1 |
| Cano, EL; Miyares, MA | 1 |
| Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Garber, ST; Schmidt, RH; Sivakumar, W | 1 |
| Okada, K; Okada, M | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| DiNicolantonio, JJ | 1 |
| Hoylaerts, MF; Kauskot, A; Peetermans, WE; Schneewind, O; van Ryn, J; Vanassche, T; Verhaegen, J; Verhamme, P | 1 |
| Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M | 1 |
| Palareti, G; Tripodi, A | 1 |
| Bryer, A | 1 |
| Baumgarten, P; Bohmann, F; Foerch, C; Lindhoff-Last, E; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Katsnelson, M; Moscucci, M; Sacco, RL | 1 |
| Cheng, PW; Hon, SF; Li, HL | 1 |
| Ahmed, S; Levin, V; Malacoff, R; Martinez, MW | 1 |
| Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Dreger, M; Fischer, JJ; Glinski, M; Graebner, OY; Koester, H; Kroll, F; Marais, A; Metternich, R; Michaelis, S; Schaudt, C; Schrey, AK; Sefkow, M | 1 |
| Kouides, PA; Wychowski, MK | 1 |
| Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C | 1 |
| Baker, RI; Harper, P; McLintock, C | 1 |
| Coory, MD; Martin, JH | 1 |
| Chryssidis, S; Jannes, J; Koblar, SA; Moey, AW; Robinson, M | 1 |
| Cohen, AT | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A | 1 |
| Duh, PD; Leuckx, PS; Warnez, PM | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Anatoliotakis, N; Deftereos, S; Giannopoulos, G; Kaoukis, A; Mavri, M; Pyrgakis, V; Stefanadis, C | 1 |
| Lip, GY; Marín, F; Roldán, V | 1 |
| Brodmann, M; Domanovits, H; Eber, B; Gottsauner-Wolf, M; Halbmayer, WM; Hiesmayr, JM; Kyrle, PA; Längle, F; Roithinger, FX; Watzke, H; Weltermann, A; Windhager, R; Wolf, C; Zweiker, R | 1 |
| Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL | 1 |
| Conners, JJ; Lee, VH; Prabhakaran, S | 1 |
| Kowey, PR; Naccarelli, GV | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Ilmakunnas, M; Lassila, R; Louhimo, J | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Boodhwani, M; Mastrobuoni, S; Robblee, JA | 1 |
| Schulman, S | 4 |
| Lewalter, T | 1 |
| Albaladejo, P; Crackowski, JL; Cracowski, JL; Hodaj, E; Marlu, R; Paris, A; Pernod, G | 1 |
| Vanerio, G; Vidal, A | 1 |
| Lip, G | 1 |
| Firriolo, FJ; Hupp, WS | 1 |
| Little, JW | 1 |
| Das, P; Jha, SK; Kabra, R; Koshy, SK; Shaheen, MH | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| El Khoury, R; Lopez, G; Misra, V; Sangha, N | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Freeman, MK; Hughes, PJ | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Garcia, DA; Granger, CB | 1 |
| Goel, R; Srivathsan, K | 1 |
| Fugate, JE; Lanzino, G; McBane, RD; Rabinstein, AA | 1 |
| Bhatt, DL; Kar, S | 1 |
| Ataullakhanov, FI; Panteleev, MA; Sinauridze, EI | 1 |
| Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Finsterer, J; Rakusan, S; Stöllberger, C; Wimpissinger, FT | 1 |
| Diener, HC; Hohnloser, SH | 1 |
| Levi, M | 1 |
| Ansell, J; Mantha, S | 1 |
| Cheng, G; Tsui, KK; Wong, RS; You, JH | 1 |
| Radecki, RP | 1 |
| Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC | 1 |
| Franks, AS; Freshour, JE; Hudson, JQ; Stevens, AB | 1 |
| Dee, S; Jayathissa, S; Thorne, KM | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Larsen, TB; Rasmussen, LH; Skjøth, F | 1 |
| Dumenil, AS; Galbois, A; Lillo-Le Louët, A; Offenstadt, G; Samama, MM; Soufir, L; Wolf, M | 1 |
| Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E | 1 |
| Takahashi, N | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Reinke, T | 1 |
| Boesen, K; Ito, S; Kernan, L; Shirazi, F | 1 |
| Fareed, J; Kalodiki, E; Lewis, B | 1 |
| Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
| Barry, M; McCullagh, L | 1 |
| Reed, SD | 1 |
| Dickneite, G; Doerr, B; Herzog, E; Kaspereit, FJ; Pragst, I; van Ryn, J; Zeitler, SH | 1 |
| Bilen, O; Teruya, J | 1 |
| Stief, TW | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Berthold, HK | 1 |
| Grigor'ev, EV; Merkulov, IV; Momot, AP; Panov, MIu; Tsyvkina, LP | 1 |
| Huang, C; Shin, J; Siu, M; Vu, L; Wong, S | 1 |
| Baumhäkel, M; Böhm, M; Kratz, MT; Lee, IO; Schirmer, SH | 1 |
| Harenberg, J; Marx, S; Wehling, M | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Feuring, M; Friedman, RJ; Hantel, S; Huo, M; Noack, H | 1 |
| Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A | 1 |
| Zhang, S | 1 |
| Bark, N; Blombäck, M; He, S; Wallèn, H | 1 |
| Al-Sallami, HS; Duffull, SB; Faed, JM; Wright, DF; Zufferey, PJ | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K | 1 |
| Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC | 1 |
| Friedman, J; Kozak, N; Schattner, A | 1 |
| Mandel, RJ; Sibley, PA | 1 |
| Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K | 1 |
| Baroody, SC; Elapavaluru, S; Horn, ET; Sokos, G; Wanek, MR | 1 |
| Griffiths, M; Scully, C | 1 |
| Taylor, J | 3 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Crijns, HJ; Pisters, R; Ten Cate, H | 1 |
| Nguyen, T; Wong, E | 1 |
| Bohmann, F; Foerch, C; Lindhoff-Last, E; Mirceska, A; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Crockett, MT; Kavanagh, EC; Moynagh, MR | 1 |
| Alonso-Coello, P; Guyatt, G; Zhou, Q | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Strang, J; Travis, E | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Chan, GT; Eaddy, NS; Jones, SD | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS | 1 |
| Amital, H; Furer, A; Karplus, R; Michael, L; Twig, G; Yaniv, G | 1 |
| Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC | 1 |
| Crowther, M; Rochwerg, B; Spyropoulos, A; Xenodemetropoulos, T | 1 |
| Basciano, P; Chen, BC; Garlich, FM; Hoffman, RS; Howland, MA; Nelson, LS; Smith, SW; Viny, AD | 1 |
| Baglin, T; Keeling, D; Kitchen, S | 1 |
| Costopoulos, C; Gorog, DA; Kukreja, N; Niespialowska-Steuden, M | 1 |
| Adachi, T; Isoda, K; Kimura, T; Yokoi, K | 1 |
| Dumkow, LE; Jennings, DL; Peters, M; Voss, JR | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Cheema, AA; Jones, P; Konduru, SV; Li, Y; Ramza, B; Wimmer, AP | 1 |
| Marrone, AC; Marrone, LC | 1 |
| Curnow, J; Dunkley, S; Kershaw, G; Khoo, TL; Reddel, CJ; Weatherburn, C | 1 |
| Boodhwani, M; Hynes, M; Labinaz, M; Price, J; Ruel, M | 1 |
| Brunner, K; Ehrenschwender, M; Koessler, J; Steigerwald, U | 1 |
| Esmon, CT | 1 |
| Le Heuzey, JY | 1 |
| Tripodi, A | 3 |
| Badenco, N; Cador, R; Cazeau, S; Delos Paquet, A; Dreyfus, J; Moubarak, G; Simion, C | 1 |
| Graf, L; Tsakiris, DA | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Boga, T; Michel, J; Mundell, D; Sasse, A | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Merli, GJ | 1 |
| Aalbers, J; Hardy, G | 1 |
| Favaloro, EJ; Lippi, G | 2 |
| Donato, G; Durin, O; Foffa, A; Inama, G; Nanetti, M | 1 |
| Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE | 1 |
| Davies, R | 1 |
| Brasselet, C; Duval, S | 1 |
| Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S | 1 |
| Aalbers, J | 2 |
| Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM | 2 |
| Bauersachs, R; Bode, C; Debus, ES; Gawaz, M; Gerlach, H; Haas, S; Hach-Wunderle, V; Lindhoff-Last, E; Riess, H; Schellong, S; Schinzel, H; Spannagl, M | 1 |
| Loor, MM; Moorman, ML; Obeng-Gyasi, S; Samotowka, MA | 1 |
| Pieracci, FM | 1 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| Nagler, M; Wuillemin, W | 1 |
| Haschke, M | 1 |
| Chang, CJ; Chen, SA; Chen, YC; Chen, YJ; Kao, YH; Lin, YK | 1 |
| Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Rami, BK | 1 |
| Eikelboom, JW; Quinlan, DJ; Weitz, JI | 1 |
| Cirra, VR; Kamboj, J; Kamboj, R; Kottalgi, M; Shah, N | 1 |
| Amir, MK; Heard, K; Maddry, JK; Sessions, D | 1 |
| Barrios, V; Escobar, C | 2 |
| Dabitz, R; Ochs, G | 1 |
| Crijns, HJ; Lane, DA; Lip, GY; Nieuwlaat, R; Pisters, R | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Okada, Y; Yasaka, M | 2 |
| Perrier, A | 1 |
| Wooten, JM | 1 |
| Kapadia, N; Lynch, CA; Phanco, SE; Woo, JS | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Chang, DN; Chin, AI; Dager, WE | 1 |
| Crowther, MA; Siegal, DM | 1 |
| Ortel, TL | 1 |
| Gross, PL; Weitz, JI | 1 |
| Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M | 1 |
| Herring, VL; Hu, ZY; Laizure, SC; Parker, RB | 1 |
| Akritidis, N; Gkabrelas, K; Tsoumpris, A; Tzimas, T | 1 |
| Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E | 1 |
| Pawlikowska, Z; Szponar, J | 1 |
| Coccheri, S; Orlando, D | 1 |
| Agnelli, G; Verdecchia, P | 1 |
| Du, S; Giese, C; Harenberg, J; Krämer, R; Krämer, S; Schulze, A; Weiss, C | 1 |
| Kanorsky, SG; Shevelev, VI | 1 |
| Deitelzweig, SB | 1 |
| Eichler, K; Plessow, R; Pletscher, M; Wieser, S | 1 |
| Eraso, LH; Merli, GJ; Perez, A | 1 |
| Cucchiara, B; Kasner, SE; Messe, S; Mullen, MT; Rybinnik, I | 1 |
| Best, M; Jones, QC; Palmer, K; Wathen, CG | 1 |
| Chance, EA; Huang, GS | 1 |
| Brill, D | 1 |
| Greenspon, AJ | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Debue, JM; Guinet, C; Le Flem, L; Ninin, E; Samama, MM | 1 |
| Chen, Z; Chintala, M; Ogletree, ML; Plump, AS; Wang, L; Wu, W; Xu, Y | 1 |
| Bernard, ML; Brabham, WW; Cuoco, F; Gold, MR; Leman, RB; Netzler, PC; Rowley, CP; Sidney, DS; Sturdivant, JL; Wharton, JM | 1 |
| Livio, F | 1 |
| Grove, EL; Husted, SE; Kraglund, KL; Modrau, B | 1 |
| Alvarez, M; de Gea-García, JH; Jiménez-Parra, JD; Ruiz-Villa, G | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Helin, TA; Joutsi-Korhonen, L; Lassila, R; Pakkanen, A | 1 |
| Dabage, N; Muniz, J; Paixao, R; Zaleski, M | 1 |
| Breik, O; Devitt, P; Tadros, R | 1 |
| Re, G; Toni, D | 1 |
| McLellan, AJ; Schlaich, MP | 1 |
| Clemens, A; Formella, S; Friedman, J; Härtter, S; Khadzhynov, D; Lehr, T; Liesenfeld, KH; Moschetti, V; Neumayer, HH; Peters, H; Slowinski, T; Wagner, F; Wiegert, E | 1 |
| Garcia, DA; Rojas-Hernandez, CM | 1 |
| Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW | 1 |
| Abrahám, P; Andréka, P; Csillik, A; Földesi, C; Fontos, G; Kardos, A; Kis, Z; Pál, M; Som, Z; Szatmári, A; Temesvári, A | 1 |
| Kræmmer Nielsen, H | 1 |
| Buch, TN; Holm, J; Munck, LK | 1 |
| Holm, J; Taskiran, M | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S | 1 |
| Connors, JM | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Alikhan, R; Baglin, T; Benson, G; Green, L; Keeling, D; Marshall, S; Patel, R; Pavord, S; Rayment, R; Rose, P; Tait, C | 1 |
| Devlin, HL; Hosman, AE; Shovlin, CL | 1 |
| Ageno, W; Bozzato, S; Donadini, MP; Riva, N | 1 |
| Diao, XJ; Gong, GQ; He, GW; Li, F; Xu, YG; Yang, WH; Yang, XZ | 1 |
| Luettgen, J; White, A; Wong, PC | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Dolgin, E | 1 |
| Fountzilas, C; George, J; Levine, R | 1 |
| Dager, WE; Gosselin, RC; Roberts, AJ | 1 |
| Canada, K; Litzenburger, T; Nar, H; Newsome, C; Park, J; Schiele, F; Sepulveda, E; van Ryn, J | 1 |
| Fritsma, GA | 1 |
| Reichman, ME; Southworth, MR; Unger, EF | 1 |
| Eby, CS | 1 |
| Aubert, J; Delalande, JP; Skowronski, P | 1 |
| Roldán Schilling, V; Vicente García, V | 1 |
| Guijarro Merino, R; Villalobos Sánchez, A | 1 |
| Nieto Rodríguez, JA | 1 |
| Marchena Yglesias, PJ | 1 |
| Hernández, M; Suárez, C | 1 |
| Fernández, D; Heras, M; Penela, D | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Torres, LM | 1 |
| Camarero, MO; Castaño, MP; Milla, SL; Piñero-Saavedra, M | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 2 |
| Arkin, CF; Aron, JL; Gosselin, R; Mantha, S; Moll, S | 1 |
| Berger, R; Chase, M; Ganetsky, M; Salhanick, SD | 1 |
| Clemens, A; Formella, S; Härtter, S; Lehr, T; Liesenfeld, KH; Staab, A | 1 |
| Hoylaerts, MF; Missiakas, DM; Peetermans, M; Peetermans, WE; Schneewind, O; Van Aelst, LN; Vanassche, T; Verhaegen, J; Verhamme, P | 1 |
| Gong, GQ; He, GW; Jiang, ML; Li, YZ; Wang, XH; Xu, YG; Yang, WH; Yang, XZ; Zhou, Y | 1 |
| Kujawski, SZ; Prom, R; Rafferty, JA | 1 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| Holley, AB; King, CS; Moores, LK | 1 |
| Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP | 1 |
| Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Abi-Saleh, B; Alam, S; Baranowski, B; Bassiouny, M; Borek, PP; Callahan, T; Chung, M; Diab, M; Dresing, T; Hussein, A; Kanj, M; Khoury, M; Lindsay, BD; Martin, DO; Niebauer, M; Rickard, J; Saliba, W; Sengupta, J; Sey, A; Shao, M; Tchou, PJ; Varma, N; Wazni, O | 1 |
| Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T | 1 |
| Attia, JR; Pearce, R | 1 |
| Eikelboom, JW; Hankey, GJ | 1 |
| Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A | 1 |
| Eby, C | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Chen, BC; Dadzie, KA; Hoffman, RS; Nelson, LS; Sheth, NR; Smith, SW; Winchester, JF | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Bazargan, A; Douglas, G; McKenzie, JL | 1 |
| Bordeaux, JS; Schmitt, AR; Zender, CA | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Nagamoto, Y; Sadamatsu, K; Shiomi, T | 1 |
| Klein, M; Savage, L; Singh, S; Thomas, C | 1 |
| Chevalier, J; de Pouvourville, G; Giroud, M | 1 |
| Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Graff, J; Harder, S | 1 |
| Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N | 1 |
| Harris, K; Mant, J | 1 |
| Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD | 1 |
| Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP | 1 |
| Yasaka, M | 1 |
| Darius, H; Sommer, S | 1 |
| Avila, C; Gullett, D; Johnson, ES; Kokaram, CR; Parra, MW; Wichner, ZA; Zucker, L | 1 |
| Awad, AJ; Coumans, JV; Nahed, BV; Stapleton, CJ; Walcott, BP; Yanamadala, V | 1 |
| Bonar, R; Butler, J; Favaloro, EJ; Marsden, K | 1 |
| Gonsalves, WI; Patnaik, MM; Pruthi, RK | 1 |
| Nutescu, EA | 1 |
| Kalus, JS | 1 |
| Lane, DA; Millar, CM | 1 |
| Atay, JK; Barnes, GD; Coatney, J; Ehle, M; Fanikos, J; Froehlich, JB; Goldhaber, SZ; Piazza, G | 1 |
| Pelargonio, G; Perna, F | 1 |
| Arachchillage, DJ; Cohen, H | 1 |
| Beaume, J; Cotte, J; Cungi, PJ; Esnault, P; Gaillard, PE; Prunet, B | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Bergman, E; Braun, OÖ; Smith, JG; Svensson, P; van der Pals, J; Wieloch, M | 1 |
| Connolly, SJ; Korhonen, M; Monz, BU; Noack, H; Pooley, J | 1 |
| Andrews, C; Bohm, N; Cearley, M; Chalela, J; Neyens, R | 1 |
| Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R | 1 |
| Abel, TJ; Greenlee, JD; Grossbach, A; Howard, MA; Jackson, AW; Viljoen, SV; Wassef, SN | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Bandali, F; Brunetti, L | 1 |
| Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y | 1 |
| Bett, N; Hamilton-Craig, C; Luis, C; Luis, SA; Poon, K; Shukla, A | 1 |
| Micieli, A; Singh, SM; Wijeysundera, HC | 1 |
| Heidenreich, PA | 1 |
| Lal, Y; Van Heukelom, J | 1 |
| Ajiro, Y; Iwade, K; Morita, S; Uchida, Y | 1 |
| Einecke, D | 2 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Bender, M | 1 |
| Hallows, KR; Henry, BL; Maw, TT; Nolin, TD; Pastor-Soler, NM; Singh, T; Unruh, ML | 1 |
| Brardjanian, S; Coton, T; Diallo, I; Guisset, M; Jourdan, S; Mallaret, C | 1 |
| Bauer, KA | 1 |
| Cook, AM; Deal, AM; Funk-Adcock, D; Gosselin, R; Hawes, EM; Jeanneret, C; Moll, S; Taylor, JM; Whinna, HC; Winkler, AM | 1 |
| Bereczki, D; Béres-Molnár, KA; Folyovich, A; Vadasdi, K; Varga, V | 1 |
| Andersen, G; Damgaard, DW; Fink-Jensen, V; Schmitz, ML; Simonsen, CZ | 1 |
| Baron, TH; Kamath, PS; McBane, RD | 1 |
| Klein, HH | 1 |
| Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E | 1 |
| Bogdanov, A; Dalton, E; Sandhu, PS; Wilson, C | 1 |
| Hagen, G; Hamidi, V; Klemp, M; Reikvam, Å; Ringerike, T | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Verheugt, FW | 1 |
| Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Breuer, L; Köhrmann, M; Ringwald, J; Schwab, S | 1 |
| Butler, J; Chunilal, S; Hapgood, G; Malan, E; Tran, H | 1 |
| Antovic, JP; Beck, O; Boija, EE; Eintrei, J; Hjemdahl, P; Malmström, RE; Norberg, EM; Onelöv, L; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M; Söderblom, L | 1 |
| Han, SY; Lee, PY; Miyahara, RK | 1 |
| Khan, A; Rahmat, N | 1 |
| Pollack, CV | 1 |
| Gong, IY; Kim, RB | 1 |
| Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Keighley-Jones, L; Nash, MJ; Pike, G; Thachil, J | 1 |
| Diener, HC | 1 |
| Douketis, J; Lang, ES; Lazo-Langner, A | 1 |
| Douketis, J; Liew, A | 1 |
| Campos, K; Coulter, S | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Baruch, L | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Crowther, MA; Daw, HA; Fawole, A | 1 |
| Páramo, JA | 1 |
| Aizawa, T; Kano, H; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Tanabe, H; Uejima, T; Yajima, J; Yamashita, T | 1 |
| Gommans, J; Harper, P; Jayathissa, S | 1 |
| Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM | 1 |
| Henry, RG; Miller, CS; Romond, KK | 1 |
| Eikelboom, JW; Robinson, M; Schulman, S; Shortt, B | 1 |
| Bhimani, AA; Hong, M | 1 |
| Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Joutsi-Korhonen, L; Lassila, R; Pétas, A; Rannikko, AS; Säily, VM; Taari, K | 1 |
| Collins, J; Eaddy, N; Lowe, MP; Yehia, M | 1 |
| Berns, JS; Chaknos, CM; Knauf, F; Perazella, MA | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Bamimore, A; Mounsey, JP | 1 |
| Djalali, S | 1 |
| Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R | 1 |
| Atar, S; Brezins, M; Shtiwi, S; Shturman, A; Wishniak, A | 1 |
| Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Doppalapudi, H; Gunter, A; Jennings, JM; Kay, GN; McElderry, HT; Osorio, J; Plumb, VJ; Robichaux, R; Yamada, T | 1 |
| Asirvatham, SJ; Noheria, A | 1 |
| Aguilar, MI; Freeman, WD; Kuo, RS | 1 |
| Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L | 1 |
| Bertoletti, L; Da Costa, A; Durupt, S; Epinat, M; Laporte, S; Lega, JC; Mismetti, P | 1 |
| Hiraoka, F; Ide, T; Murao, M; Oshiro, N; Takami, H | 1 |
| Baumann Kreuziger, LM; Reding, MT | 1 |
| Dalen, JE | 1 |
| DeRemer, CE; Elewa, HF; Gujral, J; Joshua, TV; Keller, K | 1 |
| Bell, S; Dawes, M; Nand, J | 1 |
| Fanikos, J | 1 |
| Dinkel, J; Foerch, C; Gupta, R; Hayakawa, K; Karatas, H; Lauer, A; Leung, W; Lo, EH; Schlunk, F; Steinmetz, H; Won, SY | 1 |
| Davis, C; Lee, M; Robertson, C; Shivakumar, S | 1 |
| Eder, V; Haring, HP; Müller, P; Nesser, HJ; Nußbaumer, K; Sonnberger, M; Topakian, R; Trenkler, J; Windpessl, M | 1 |
| Alvrtsyan, H; Francis, K; Matchar, D; Miyasato, G; Rao, Y; Sanchez, H; Sander, S; Siu, K; Walker, D; Yu, C; Zalesak, M | 1 |
| Wanat, MA | 1 |
| Baglin, T | 1 |
| Avorn, J | 1 |
| Barry, M | 1 |
| Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C | 1 |
| Ansell, J; Shameem, R | 1 |
| Lip, GY; Potpara, TS | 1 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Bennaghmouch, N; Ten Berg, JM | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Hollis, S | 1 |
| Lip, GY; Van Gelder, IC; Van Veldhuisen, DJ | 1 |
| Doraiswamy, VA; Gesheff, MG; Gurbel, PA; Slepian, MJ; Tantry, US | 1 |
| Bischof, EF; Cheungpasitporn, W; Ratanapo, S; Srivali, N; Ungprasert, P | 1 |
| Rosenfeld, JV; Schaerf, NB; Thomas, PA | 1 |
| Hylek, EM | 1 |
| Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU | 1 |
| Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S | 1 |
| Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Hayashida, K; Koga, Y; Matsuura, T; Mine, D; Nagamoto, Y; Okahara, A; Sadamatsu, K; Shiomi, T; Shirahama, T; Takegami, K; Yoshida, K | 1 |
| Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H | 1 |
| Brueckmann, M; Connolly, S; Eikelboom, J; Ezekowitz, M; Le Heuzey, JY; Marijon, E; Pogue, J; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Shavadia, J; Welsh, RC | 1 |
| Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW | 1 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Cram, P; Mazur, A; Reisinger, HS; Vaughan Sarrazin, MS; Ward, M | 1 |
| Hayashi, Y; Miyagi, Y; Ootani, A | 1 |
| Conway, SE; Schaeffer, S | 1 |
| Azuma, S; Lum, CJ | 1 |
| Amara, W; Guedeney, P; Iusuf, A | 1 |
| Holmes, D | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ | 1 |
| Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S | 1 |
| Atar, D; Ghanima, W; Sandset, PM | 1 |
| Paré, G; Ross, S | 1 |
| Damgaard, D; Simonsen, CZ; Steiner, T; Tietze, A | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Sarode, R; Yates, S | 1 |
| Akgüllü, C; Eryılmaz, U; Kurtoğlu, T | 1 |
| Takeuchi, H | 2 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Chandler, WL | 1 |
| Bin Abdulhak, AA; Khan, AR; Tleyjeh, IM; Wimmer, AP | 1 |
| Blum, J; Carreiro, S; Hack, JB | 1 |
| Diogène, E; Troncoso, A | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Braun, G; Messmann, H | 1 |
| Cove, CL; Hylek, EM | 1 |
| Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S | 1 |
| Degirmenci, SE; Steib, A | 1 |
| Borobia, AM; Casado, MS; Díaz, MQ; Fabra, S; García-Erce, JA; Núñez, MA; Samama, CM; Virto, AM | 1 |
| Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB | 1 |
| Fries, D; Giurea, A; Gütl, M; Halbmayer, WM; Kozek-Langenecker, S; Pachucki, A; Roithinger, F; Steinlechner, B; Thaler, H; Weltermann, A | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM | 1 |
| Frölich, L; Harenberg, J; Krejczy, M; Marx, S; Obermann, K; Wehling, M | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Wood, P | 1 |
| Finsterer, J; Krutisch, G; Stöllberger, C | 1 |
| Adam, G; Akbal, E; Asik, M; Bilen, Oİ; Binnetoglu, E; Gunes, F; Sen, H; Temiz, A; Ukinc, K | 1 |
| González-Rico, MA; Juan-García, I; Miguel-Carrasco, A; Puchades-Montesa, MJ; Ramos-Tomás, C; Ribés-Cruz, JJ; Solís-Salguero, MA; Tejedor-Alonso, S; Tomás-Simó, P; Torregrosa-Maicas, I; Zambrano-Esteves, P | 1 |
| Celik, S; Sipahi, I; Tozun, N | 1 |
| Katz, MH | 1 |
| Edwin, SB; Lucey, MF; Tedders, KM | 1 |
| Dager, WE; Dwyre, DM; Gosselin, RC | 1 |
| Darko, W; Miller, CD; Probst, LA; Sidman, E | 1 |
| Faust, AC; Kawalsky, D; Smith, MB | 1 |
| Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Omote, Y; Yamashita, T; Yunoki, T | 1 |
| Manning, JA | 1 |
| Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C | 1 |
| Hu, ZY; Zhao, Y | 1 |
| Kitazono, T | 1 |
| Laffan, M; Shapiro, S | 1 |
| Conway, SE; Harrison, DL; Schaeffer, SE | 2 |
| Lee, CL; Tsao, HM; Wang, HH | 1 |
| Ragni, MV | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S | 1 |
| Albenque, JP; Boveda, S; Marijon, E; Providência, R | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Avram, MJ; Benzon, HT; Bonow, RO; Green, D | 1 |
| Bounameaux, H; Verhamme, P | 1 |
| Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S | 1 |
| Aumann, V; Boxberger, N; Hartung, KJ; Heim, MU; Siegemund, A | 1 |
| Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T | 1 |
| Almutawa, M; Ghanny, S; Goy, JK; Nahirniak, S; Ritchie, B; Schulman, S | 1 |
| Barillari, G; Cheng, JW | 1 |
| Ditch, K; Miller, MA; Ross, B; Tran, M | 1 |
| Crowther, MA; Garcia, DA; Siegal, DM | 1 |
| Best, AJ; Bloch, BV; Patel, V | 1 |
| Briggs, N; De Silva, K; Dean, J; Dee, S; Jayathissa, S; Reid, S; Taylor, J; Thorne, K | 1 |
| Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A | 1 |
| Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C | 1 |
| Laroche, JP | 1 |
| Adcock, D; Gosselin, R; Hawes, E; Moll, S | 1 |
| Diener, HC; Weber, R | 1 |
| Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB | 1 |
| Chantrathammachart, P; Hebbel, RP; Key, NS; Mackman, N; Mickelson, J; Monroe, DM; Pawlinski, R; Sparkenbaugh, EM; van Ryn, J | 1 |
| Bajorek, B; Wang, Y | 1 |
| Goto, S; Tomita, A | 1 |
| Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
| Hanon, O | 1 |
| Rondina, MT; Vazquez, S; Vo, T | 1 |
| Darvish-Kazem, S; Douketis, JD; Liew, A | 1 |
| Carley, B; Griesbach, S; Krueger, K; Larson, T | 1 |
| Gálity, H; Gombár, C; Horvath, G; Sisák, K; Tóth, K | 1 |
| Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA | 1 |
| Grottke, O; Rossaint, R; Spronk, HM; van Ryn, J | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Meijers, JC; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Faust, AC; Peterson, EJ | 1 |
| Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H | 1 |
| Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Miller, MP; Nordenholz, KE; Trujillo, TC | 1 |
| Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J | 1 |
| Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Acket, B; Bagheri, H; Bourrel, R; Lavezzi, O; Molinier, A; Montastruc, JL | 1 |
| Foerch, C; Lauer, A; Leung, W; Lo, EH; Lok, J; Schaefer, JH; Van Cott, EM; van Leyen, K; van Ryn, J; Whalen, M; Wu, L | 1 |
| Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
| Hayama, M; Inoue, H; Mio, T; Wada, H | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K | 1 |
| Finsterer, J; Krutisch, G; Stöllberger, C; Wolf, HM | 1 |
| Fredenburgh, JC; Liao, P; Roberts, RS; Weitz, JI; Yau, JW | 1 |
| Ackermann, D; Bartels, DB; Clemens, A; Diener, HC; Dubner, SJ; Halperin, JL; Huisman, MV; Lip, GY; Ma, CS; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Groh, C; Passman, R; Yadlapati, A | 1 |
| Herrmann, E; Herth, N; Kasper, A; Lindhoff-Last, E; Linnemann, B; Mani, H; Pfeilschifter, W; Schuettfort, G; Weil, Y; Wendt, T | 1 |
| Hoffman, RS; Mercurio-Zappala, M; Su, M | 1 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Htun, KT; McFadyen, J; Tran, HA | 1 |
| Brunetti, L; Chen, C; White, J | 1 |
| Keeling, D; Wong, H | 1 |
| Antoniazzi, S; Berdaï, D; Clementi, E; Conti, V; Salvo, F | 1 |
| Butcher, K; Nahirniak, S; Stang, L; Szkotak, AJ | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C | 1 |
| Bassand, JP | 1 |
| Hickel, C | 1 |
| Ago, T; Fujimoto, S; Kameda, K; Kitazono, T; Kokuba, K; Komori, M; Matsuoka, H; Nagata, S; Okada, Y; Shono, T; Yasaka, M; Yoshida, M | 1 |
| Cordova, EG; del Aguila, D; Salazar, CA | 1 |
| Harder, S; Meyer Dos Santos, S | 1 |
| Arya, R; Couchman, L; Flanagan, RJ; Gous, T; Paradzai, C; Patel, JP | 1 |
| Beyer-Westendorf, J; Ebertz, F; Förster, K; Gelbricht, V; Hänsel, U; Köhler, C; Kuhlisch, E; Röder, I; Röllig, D; Schreier, T; Stange, T; Thieme, C; Tittl, L; Weiss, N; Werth, S | 1 |
| Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T | 1 |
| Boyle, ME; Fisher, S; Ishimoto, J; Kiser, TH; Lind, SE; Trujillo, TC | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Fenger-Eriksen, C; Grove, EL; Münster, AM | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Julius, CJ; Negrete, H; Roy, P; Sarac, E; Shafi, ST | 1 |
| Campbell, S; Carrizo, A | 1 |
| Ibrahim, S; Jespersen, J; Poller, L | 1 |
| Douketis, J; Ing, E | 1 |
| Gislason, G; Sørensen, R | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brannath, W; Schmidt, S | 1 |
| Brieger, D | 1 |
| Bonner, E; Finsterer, J; Stöllberger, C | 1 |
| Hirano, T | 1 |
| Aleksa, K; Bapat, P; Berger, H; Kedar, R; Koren, G; Lubetsky, A; Matlow, JN | 1 |
| Ardissino, D; Cervellin, G; Lippi, G; Quintavalla, R | 1 |
| Arnold, DM; Bhakta, V; Crowther, MA; Eltringham-Smith, LJ; Lambourne, MD; Sheffield, WP | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Birnie, DH; Essebag, V; Healey, JS | 1 |
| Alegret, JM; Arias, MA; Martínez-Rubio, A; Martínez-Sande, JL; Ràfols, C; Rebollo, P; Viñolas, X | 1 |
| John, A; Michel, MS | 1 |
| Foley, J; Kirchhof, P; Lip, GY | 1 |
| Anderson, DR; Goralski, KB; Morrison, M; Mossop, P; Sleno, L; Soroka, SD; Wang, Y; Wilson, JA | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Bouvaist, H; Ennezat, PV; Gagliardi, L; Guerbaai, RA; Marlière, S | 1 |
| Dempfle, CE | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Akasheva, DU; Tkacheva, ON | 1 |
| Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC | 1 |
| Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
| Diogo, C; Duarte, J; Nzwalo, H; Pestana, P; Rita, H; Sobral, S; Sousa E Costa, J | 1 |
| Aziz, H; Davis, K; Ditillo, M; Friese, R; Hays, D; Joseph, B; Pandit, V; Rhee, P; Sadoun, M | 1 |
| Zateĭshchikov, DA; Zotova, IV | 1 |
| Abdollah, H; Baranchuk, A; Haley, C; Michael, K; Mohajer, K; Redfearn, DP; Simpson, CS; Somani, R | 1 |
| Breik, O; Cheng, A; Goss, A; Sambrook, P | 1 |
| Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD | 1 |
| Inaba, T; Ishikawa, S; Izumikawa, K; Kawai, K; Kawai, Y; Miyoshi, M; Mizukawa, S; Sakakihara, I; Wato, M | 1 |
| Brinkman, HJ; Dinkelaar, J; Harenberg, J; Leyte, A; Patiwael, S | 1 |
| Casper, M; Lammert, F; Zimmer, V | 1 |
| Albertson, TE; Cantrell, FL; Clark, RF; Minns, AB; Smollin, C; Stevenson, JW; Tomaszewski, C | 1 |
| Engström, M; Johansson, PI; Nilsson, CU; Ostrowski, SR; Sølbeck, S | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Hess, T; Konturek, P | 1 |
| Lévy, S | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Akl, EA; Barba, M; Kahale, L; Labedi, N; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I | 1 |
| Berthold, C; Boecher-Schwarz, H; Dooms, G; Gunness, VR; Hana, A; Hertel, F; Koy, J; Matgé, G; Standhardt, H | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Hale, SL; Kloner, RA | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| AbuDagga, A; Fu, AC; Kwong, WJ; Stephenson, JJ; Tan, H; Weintraub, WS | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Rodgers, GM; Win, K | 1 |
| Cohen, D | 2 |
| Charlton, B; Redberg, R | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Cohen, MR; Mattison, DR; Moore, TJ | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Kelm, M; Nitschmann, S; Zeus, T | 1 |
| Artunc, F; Baumann, D; Haap, M; Jaschonek, K; Krämer, B; Peter, A; Rettig, I; Schreieck, J; Tsaousidis, C; Wallwiener, D | 1 |
| McCormick, NJ; Meechan, JG; Moore, UJ; Norouzi, M | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF | 1 |
| Barucci, R; Fattirolli, F; Fracchia, S; Mannarino, G; Orso, F; Pratesi, A | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B | 1 |
| Dobrotová, M; Galajda, P; Ivanková, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J | 1 |
| Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S | 1 |
| Akwaa, F; Spyropoulos, AC | 1 |
| Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Hirota, K; Kono, M; Koumura, C; Sakai, T; Tojima, H; Yokoe, A | 1 |
| Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT | 1 |
| Flick, MJ; Joshi, N; Kassel, KM; Kopec, AK; Luyendyk, JP; Sullivan, BP; Towery, KL | 1 |
| Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A | 1 |
| Boonen, K; Brunsveld, L; Emmen, JM; Schellings, MW; Schmitz, EM; van de Kerkhof, D; van den Heuvel, DJ; van der Graaf, F; van Dongen, JL | 1 |
| Steurer, J | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Cotton, BA; Johansson, PI; Meyer, AS; Meyer, MA; Ostrowski, SR; Schött, U; Solbeck, S; Stensballe, J | 1 |
| Moorman, ML; Nash, JE; Stabi, KL | 1 |
| Levy, JH | 1 |
| Grottke, O; Spronk, H; van Ryn, J | 1 |
| Antovic, JP; Beck, O; Eintrei, J; Hjemdahl, P; Malmström, RE; Muhrbeck, J; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M | 1 |
| Bihan, K; Ferreol, L; Funck-Brentano, C; Hulot, JS; Korostelev, M; Tissot, N; Zahr, N | 1 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Carroll, VS; Frei, J | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Carrieri, C; Colucci, M; Incampo, F; Semeraro, N | 1 |
| Lane, DA; Lip, GY; Senoo, K | 1 |
| Czubek, U; Góralczyk, T; Undas, A; Zalewski, J | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Crowther, MA; Cuker, A; Garcia, DA; Siegal, DM | 1 |
| Blann, AD; Lip, GY | 1 |
| Bennell, MC; Krahn, M; Micieli, A; Pham, B; Singh, SM; Wijeysundera, HC | 1 |
| Banfi, R; Fallani, F; Palazzi, N; Pugi, A | 1 |
| Bailleul, E; Chatelain, B; Coucke, W; Demulder, A; Devreese, K; Douxfils, J; Jochmans, K; Mullier, F; Soumali, MR; Van Blerk, M; Van de Walle, P; Vernelen, K; Wijns, W | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Bernstein, RA; Eikelboom, J; Huisman, MV; Kamphuisen, P; Levy, JH; Pollack, CV; Sellke, FW; Steiner, T; Weitz, JI | 1 |
| Demulder, A; Safouris, A; Triantafyllou, N; Tsivgoulis, G | 1 |
| Connolly, SJ; Wallentin, L; Yusuf, S | 1 |
| Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Howell, G; Pluym, M | 1 |
| Cairns, JA; Connolly, S; Cox, JL; Dorian, P; Gladstone, D; Healey, JS; Ivers, N; Leblanc, K; Macle, L; McMurtry, MS; Mitchell, LB; Nattel, S; Stiell, IG; Verma, A | 1 |
| Husein, H; Samo, S; Sherid, M; Sifuentes, H; Spurr, C; Sridhar, S; Sulaiman, S; Thiruvaiyaru, D; Tupper, R | 1 |
| Branch, J; Chuang, A; Cutler, TW; Huynh, TD; Pon, T; White, R; Witt, RG | 1 |
| Ammollo, CT; Colucci, M; Semeraro, N; Testa, S; Visino, F; Zaccaria, F | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Colucci, M; Semeraro, N; Visino, F; Zaccaria, F | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Kovács, T | 1 |
| Cakmak, MA; Cinar, N; Karsidag, S; Sahin, S | 1 |
| Doering, M; Egidy, C; Gehrke, T; Kendoff, D; Krettek, C; Mommsen, P; R O Hrs, E | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R | 1 |
| Cui, J; Li, Z; Liu, C; Wu, B | 1 |
| Baik, SH; Hernandez, I; Piñera, A; Zhang, Y | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Beyer-Westendorf, J | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Ansell, J; Bakhru, S; Costin, J; Laulicht, B; Steiner, S | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 2 |
| Eikelboom, JW; Hart, RG | 1 |
| Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY | 1 |
| Adcock, D; Francart, SJ; Gosselin, RC; Grant, RP; Hawes, EM; Moll, S | 1 |
| Getta, B; Hsu, D; Motum, P; Muller, N; Rosenfeld, D; Zebeljan, D | 1 |
| Levy, JH; Samama, CM | 1 |
| Hirose, Y; Inamasu, J; Tanoue, S; Toyama, H; Yamada, M | 1 |
| Bamps, S; Decramer, T; Theys, T; Thijs, V; Van Loon, J; Vandenbussche, N; Verhamme, P | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H | 1 |
| Ashikhmina, E; Connors, JM; Davidson, M; Jahanyar, J; Mizuguchi, KA; Tomasello, N | 1 |
| da Silva, RM | 1 |
| Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM | 1 |
| Beliavskaia, OO; Vavilova, TV | 1 |
| Undas, A; Zalewski, J | 1 |
| Allouche, E; Amara, W; Dompnier, A; Fromentin, S; Georger, F; Nguyen, C; Saoudi, N; Taieb, J | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Hoffman, M; Monroe, DM; Volovyk, Z | 1 |
| Peacock, WF | 1 |
| Hajhosseiny, R; Lip, GY; Sabir, I | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Briët, E; Engelfriet, PM | 1 |
| Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L | 1 |
| Belikov, LN; Savchuk, OF; Sukovatykh, BS; Sukovatykh, MB | 1 |
| Blann, AD | 1 |
| Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Bruckner, T; Hess, A; Katus, HA; Kieser, M; Mereles, D; Pohlmeier, M; Scholz, E; Schweizer, PA; Thomas, D; Zitron, E; Zylla, MM | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Bultas, J; Karetová, D | 1 |
| Cantürk, E; Güler, E; Karaca, O; Kızılırmak, F; Omaygenç, O | 1 |
| Berutti, S; Coglitore, R; Cosseddu, D; Erroi, L; Marangella, M; Migliardi, M; Montaruli, B; Sivera, P; Vitale, C | 1 |
| Harel, Z; Perl, J; Sood, MM | 1 |
| Ketha, H; Mills, JR | 1 |
| Bernier-Jean, A; Bouchard, J; Eris, JM; Ghannoum, M; Kershaw, G; Patel, JP; Roberts, DM; Tran, H; Weatherburn, C; Williamson, D | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| del Zoppo, GJ; Gu, YH; Hawkins, BT; Izawa, Y | 1 |
| Garg, P; Ripley, DP | 1 |
| Levasseur-Franklin, KE; Liotta, EM; Naidech, AM | 1 |
| Bultas, J | 1 |
| Garcia, DA; Kim, B | 1 |
| Shchendrygina, AA | 1 |
| Beauchesne, M; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Tousignant, A; Turgeon, M | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Becker, RC; Krishnamoorthy, A; Lopes, RD; Sherwood, MW | 1 |
| Oberhofer, E | 1 |
| Steiner, T | 1 |
| Powell, JR | 1 |
| Friedman, RJ; Messerschmidt, C | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Meesmann, M; Scheppach, W | 1 |
| Carey, EP; Cunningham, F; Glorioso, TJ; Ho, PM; Jackevicius, C; Lambert-Kerzner, A; Longo, L; Rose, A; Shore, S; Turakhia, MP | 1 |
| Müller, P; Windpessl, M | 1 |
| Mracsko, E; Na, SY; van Ryn, J; Veltkamp, R | 1 |
| Lane, DA; Wood, K | 1 |
| Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S | 1 |
| Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M | 1 |
| Fujino, T; Kuwahara, T; Nakajima, J; Nakashima, E; Okubo, K; Takagi, K; Takahashi, A; Takigawa, M; Tsutsui, H; Watari, Y; Yamao, K | 1 |
| Arentz, T; Jadidi, A; Lehrmann, H; Park, CI; Pruvot, E; Weber, R; Zimmermann, M | 1 |
| Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL | 1 |
| Gehrie, E; Tormey, C | 1 |
| Chen, B; Coronel, LJ; Goss, A; Soto, AG; Trejo, J; van Ryn, J | 1 |
| Chan, EW; He, Y; Lau, WC; Leung, WK; Mok, MT; Tong, TS; Wong, IC | 1 |
| Barty, R; Blostein, M; Carrier, M; Douketis, JD; Heddle, N; Lee, AY; Schulman, S; Shivakumar, S; Solymoss, S; Spencer, FA; Wang, G | 1 |
| Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N | 1 |
| Hilpert, U | 1 |
| Ameri, AA | 1 |
| Hendrickson, JE; Rinder, HM; Siddon, AJ; Tormey, CA | 1 |
| Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK | 1 |
| Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y | 1 |
| Bernstein, RA; Dubiel, R; Eikelboom, J; Glund, S; Huisman, MV; Hylek, EM; Kam, CW; Kamphuisen, PW; Kreuzer, J; Levy, JH; Pollack, CV; Reilly, PA; Sellke, FW; Stangier, J; Steiner, T; Verhamme, P; Wang, B; Weitz, JI | 1 |
| Bächli, E; Walti, C | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Ho, P; La Brooy, B; Lim, K | 1 |
| Potpara, TS | 1 |
| McBane, RD; Schaefer, JK; Wysokinski, WE | 1 |
| Curto, A | 1 |
| Torjesen, I | 1 |
| Heard, LK; Maggio, KL; Shanahan, C | 1 |
| Alonso, A; Bengtson, LGS; Chen, LY; Lutsey, PL; MacLehose, RF | 1 |
| Minhas, JS; Mistri, AK | 1 |
| Ummarino, D | 1 |
| Sugiyama, T | 1 |
| Chan, EW; Lau, WCY; Wong, ICK | 1 |
| Calkins, H; Nordaby, M | 1 |
| Seligman, SJ | 1 |
| Larsen, JM; Løfgren, B; Pareek, M | 1 |
| Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE | 1 |
| Dobrev, D; Fender, AC | 1 |
| Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR | 1 |
336 review(s) available for beta-alanine and dabigatran
| Article | Year |
|---|---|
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Orthopedics; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism; Traumatology; Treatment Outcome | 2010 |
Drug and dietary interactions of the new and emerging oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Dabigatran: the anticoagulant we have long expected?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Venous Thromboembolism | 2010 |
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Risk Assessment; Thrombin; Thromboembolism; Treatment Outcome | 2010 |
Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drugs, Investigational; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Managing bleeding complications in patients treated with the old and the new anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Polysaccharides; Protamines; Recombinant Proteins; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
Stroke in atrial fibrillation--hope on the horizon?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Heart Atria; Humans; Prostheses and Implants; Stroke; Warfarin | 2010 |
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Health Status Indicators; Humans; Risk Assessment; Stroke; Vitamin K; Warfarin | 2011 |
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Intracerebral hemorrhage: Pick your poison.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Humans; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Venous Thromboembolism; Warfarin | 2010 |
What's new in treating older adults?
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cholinesterase Inhibitors; Cognition; Dabigatran; Delirium; Dementia; Denosumab; Exercise; Fractures, Bone; Geriatrics; Humans; RANK Ligand; Vitamin D | 2010 |
Advances in the treatment of atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Dronedarone; Drug Therapy, Combination; Heart Conduction System; Humans; Pyrrolidines; Treatment Outcome | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2011 |
Atrial fibrillation in 2010: advances in treatment and management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
A new anticoagulant for a new era: review of recent data on dabigatran etexilate.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans | 2010 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Venous Thromboembolism | 2011 |
[Dabigatran, a new oral anticoagulant].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
Frontiers of anticoagulation therapy for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2011 |
New options for stroke prevention in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2010 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Characteristics of novel anticoagulants and potential economic implications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; Medication Adherence; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Vitamin K | 2011 |
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Topics: Age Factors; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Electric Countershock; Humans; Randomized Controlled Trials as Topic | 2011 |
A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Orthopedic Procedures; Risk Assessment; Venous Thromboembolism | 2011 |
Atrial fibrillation: epidemiology, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Dronedarone; Electric Countershock; Heart Rate; Humans; Prognosis; Quality of Life; Risk Factors; Thromboembolism | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Risk Factors; Stroke; Thrombin | 2011 |
New anticoagulants for prevention of stroke in patients with atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure | 2011 |
[New concepts in the therapy of atrial fibrillation].
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Electric Countershock; Humans; Pacemaker, Artificial; Pyrrolidines; Stroke; Thromboembolism | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Stroke prevention in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Catheterization; Cardiac Surgical Procedures; Dabigatran; Humans; Preventive Health Services; Stroke; Treatment Outcome; Warfarin | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Echocardiography, Three-Dimensional; Electric Countershock; Humans; International Normalized Ratio; Premedication; Randomized Controlled Trials as Topic; Risk Adjustment; Thromboembolism; Time Factors; Warfarin | 2011 |
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Partial Thromboplastin Time; Renal Dialysis | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Evidence-Based Medicine; Hemorrhage; Humans; Italy; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2011 |
Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Neurosurgical Procedures; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stockings, Compression; Surgical Procedures, Operative; Thiophenes; Urologic Surgical Procedures; Venous Thrombosis | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin | 2012 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2011 |
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Fondaparinux; Heart Valve Prosthesis Implantation; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopharmaceutics; Blood Coagulation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Approval; Drug Dosage Calculations; Drug Monitoring; Humans; Risk Assessment; Therapeutic Equivalency; Thrombin; Thromboembolism; Warfarin | 2011 |
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.
Topics: Animals; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Stroke | 2011 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin | 2011 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Venous Thromboembolism | 2012 |
Promise of factor Xa inhibition in atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors; Stroke; United States; Warfarin | 2012 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemodynamics; Hemorrhage; Humans; Risk Factors; Stroke; Therapeutic Equivalency; Treatment Outcome; Ventricular Dysfunction, Left; Warfarin | 2011 |
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Perioperative Care; Stroke; Thromboembolism; Vitamin K | 2011 |
Stroke prevention in atrial fibrillation: do we still need warfarin?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Decision Making; Factor Xa Inhibitors; Humans; Risk Factors; Stroke; Thrombin; Vitamin K; Warfarin | 2012 |
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Venous Thromboembolism; Warfarin | 2011 |
[Interpretation of hemostatic and fibrinolytic markers].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Dabigatran; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemostasis; Humans; Partial Thromboplastin Time; Plasminogen Activators; Prothrombin Time; Thrombomodulin; Warfarin | 2011 |
Pharmacological basis and clinical evidence of dabigatran therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Kidney Failure, Chronic; Thrombosis | 2011 |
Using anticoagulants to steer clear of clots.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Heparin; Humans; Thrombosis; Warfarin | 2012 |
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Thromboembolism | 2012 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
The oral thrombin inhibitor dabigatran: strengths and weaknesses.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Thrombin | 2012 |
Determination of dabigatran in human plasma samples.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Thromboembolism | 2012 |
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Humans; Risk Factors; Thromboembolism; Treatment Outcome; Venous Thromboembolism | 2012 |
Warfarin versus dabigatran: comparing the old with the new.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Warfarin | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2012 |
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Male; Stroke; Warfarin | 2012 |
Improving prevention and treatment of venous thromboembolism: clinical trial results.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; International Normalized Ratio; Liver; Myocardial Infarction; Warfarin | 2012 |
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Stroke; Warfarin | 2012 |
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Stroke | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke | 2012 |
Dabigatran: a new chapter in anticoagulation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Molecular Structure; Stroke; Thromboembolism; Treatment Outcome | 2012 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Monitoring, Physiologic; Platelet Aggregation; Stroke; Thromboembolism; Warfarin | 2012 |
[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Thrombosis; Venous Thromboembolism | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel direct factor IIa and Xa inhibitors: mechanisms of action and preclinical studies.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Humans; Prothrombin; Thrombosis | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
[Dabigatran and emergency operation on a peritonitis patient].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dialysis; Emergency Treatment; Factor VIIa; Hemorrhage; Humans; Practice Guidelines as Topic | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran and left atrial appendage thrombus.
Topics: Antithrombins; Atrial Appendage; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Diseases; Humans; Middle Aged; Thrombosis; Warfarin | 2012 |
New oral anticoagulants: will they replace warfarin?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Interactions; Factor Xa Inhibitors; Gastritis; Hemorrhage; Humans; Liver; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fibrinolytic Agents; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Intracranial Embolism; Multicenter Studies as Topic; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Single-Blind Method; Thrombophilia; Vitamin K | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Newer oral anticoagulant agents: a new era in medicine.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Dabigatran: a primer for neurosurgeons.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Hemorrhage; Dabigatran; Humans; Neurosurgery; Perioperative Care; Postoperative Complications | 2013 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
Anticoagulant therapy: basic principles, classic approaches and recent developments.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudins; Humans; Platelet Aggregation Inhibitors; Thrombin; Thromboembolism; Thrombophilia; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Complications of anticoagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Contamination; Drug Monitoring; Food-Drug Interactions; Hemorrhage; Heparin; Humans; Hypersensitivity; Injections, Subcutaneous; Necrosis; Osteoporosis; Skin Diseases; Subcutaneous Tissue; Thrombocytopenia; Warfarin | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Female; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Challenges in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; International Normalized Ratio; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2012 |
The novel oral anticoagulants: an update for the interventional radiologist.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Radiography, Interventional; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Monitoring, Ambulatory; Self Care; Stroke; Thromboembolism; Vitamin K; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
Novel oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2013 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Laboratory tests and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Morpholines; Predictive Value of Tests; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2012 |
The laboratory and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Hemostasis; Humans; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
The new oral anticoagulants and the future of haemostasis laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemostasis; Humans; Laboratories; Morpholines; Rivaroxaban; Thiophenes | 2012 |
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Drug Monitoring; Echocardiography, Transesophageal; Electric Countershock; Female; Heart Atria; Heart Rate; Hemorrhage; Humans; Male; Middle Aged; Pharmacovigilance; Risk Adjustment; Thrombosis; Treatment Outcome | 2012 |
Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Wounds and Injuries | 2012 |
[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Food-Drug Interactions; Hemostasis; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Switzerland; Thiophenes; Thromboembolism | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Evidence-Based Medicine; Hemorrhage; Humans; Risk Factors; Stroke | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
Comparing new anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K | 2012 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin | 2012 |
[New anticoagulants--are we prepared?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
[Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Practice Guidelines as Topic; Surveys and Questionnaires | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydrochloride; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Fibrinolytic Agents; Fumarates; Hemorrhage; Humans; Pharmacovigilance; Propylamines | 2013 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Thrombin inhibitors: surgical considerations and pharmacology.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Surgical Procedures, Operative | 2013 |
The novel oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Disease Management; Drug Overdose; Emergency Service, Hospital; Hemorrhage; Humans; Postoperative Hemorrhage | 2014 |
Dabigatran: life-threatening bleeding.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Risk Assessment; Risk Factors; Thrombosis; Treatment Outcome | 2013 |
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coumarins; Dabigatran; Female; Hematology; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Sex Factors; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[New approaches in the treatment of deep vein thrombosis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2012 |
[New evidence in the secondary prevention of thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Dabigatran; Fibrin Fibrinogen Degradation Products; Humans; Morpholines; Prognosis; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2012 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Withholding Treatment | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
The laboratory and the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Novel anticoagulants and laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Perioperative management of anticoagulation in elective surgery.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Diseases; Clopidogrel; Dabigatran; Elective Surgical Procedures; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Thromboembolism; Ticlopidine; Withholding Treatment | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Humans; Quality-Adjusted Life Years; Stroke; Technology Assessment, Biomedical | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
[Direct oral thrombin inhibitor, "dabigatran"].
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Warfarin | 2013 |
Dabigatran, intracranial hemorrhage, and the neurosurgeon.
Topics: Aged, 80 and over; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Neurosurgery; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
The new oral anticoagulants in clinical practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Use of new oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Breast Feeding; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Monitoring; Female; Humans; Infant, Newborn; Maternal Exposure; Morpholines; Pregnancy; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Topics: Accidental Falls; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Craniocerebral Trauma; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male | 2013 |
Dabigatran: is there a role for coagulation assays in guiding therapy?
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cholangiopancreatography, Endoscopic Retrograde; Clopidogrel; Dabigatran; Drug Interactions; Fondaparinux; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Polysaccharides; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New anticoagulants as thromboprophylaxis after total hip or knee replacement.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Patient Safety; Premedication; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Monitoring, Physiologic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Stroke; Treatment Outcome | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Hemostatic Techniques; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Stroke thrombolysis in patients taking dabigatran.
Topics: Aged; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Stroke; Thrombin Time; Thrombolytic Therapy | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Dabigatran and kidney disease: a bad combination.
Topics: Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation Tests; Charcoal; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Kidney Diseases; Plasma; Renal Replacement Therapy | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Observational Studies as Topic; Postoperative Complications; Premedication; Risk Factors; Thromboembolism; Treatment Outcome | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Intracranial Hemorrhages; Pyridines; Risk Assessment; Risk Factors; Stroke; Vitamin K | 2013 |
Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Topics: Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Postoperative Hemorrhage; Pyridines; Surgery, Oral; Tooth Extraction; Warfarin | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Warfarin | 2013 |
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Morpholines; Perioperative Care; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thrombin | 2013 |
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Perioperative Care; Stroke; Warfarin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhagic Disorders; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
[Gastrointestinal bleeding in cardiological patients].
Topics: Algorithms; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Metabolic Clearance Rate; Morpholines; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Transfusion; Rivaroxaban; Thiophenes; Vitamin K | 2013 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Stroke; Venous Thromboembolism; Warfarin | 2013 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Pharmaceutical; Gastrointestinal Hemorrhage; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2014 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Female; Half-Life; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Morpholines; Rivaroxaban; RNA Interference; Thiophenes | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulants and regional anaesthesia.
Topics: Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrhage; Humans; Incidence; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thromboembolism | 2014 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Current state of anticoagulants to treat deep venous thrombosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2014 |
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Global Health; Humans; Incidence; Ischemic Attack, Transient; Stroke; Thromboembolism | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Hemorrhage; Humans; Risk Factors; Stroke | 2014 |
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2014 |
Risk of major bleeding and the standard doses of dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Stroke; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Vitamin K | 2014 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin | 2014 |
Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Risk Factors; Stroke | 2014 |
[Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diffusion Magnetic Resonance Imaging; Humans; Infusions, Intravenous; Male; Partial Thromboplastin Time; Recombinant Proteins; Stroke; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants and oculoplastic surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cataract Extraction; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgery, Plastic; Thiophenes | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Management of anticoagulation around pacemaker and defibrillator surgery.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Defibrillators, Implantable; Humans; Intracranial Embolism; Male; Pacemaker, Artificial; Warfarin | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Practice Patterns, Physicians'; Stroke; Treatment Outcome | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
[Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2014 |
Protocol in managing oral surgical patients taking dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Female; Humans; Male; Oral Surgical Procedures; Tooth Extraction; Warfarin; Withholding Treatment | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K | 2014 |
NOAC and intracerebral bleeding--presentation of four cases and review of the literature.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Female; Humans; Hypertension; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2014 |
Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Hemorrhage; Humans; Pyrazoles; Pyridones; Risk Factors | 2014 |
Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Wounds and Injuries | 2014 |
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Precision Medicine | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Management of hemorrhage with the target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Reversal agents in development for the new oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Piperazines; Recombinant Proteins; Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomedical Research; Dabigatran; Factor Xa Inhibitors; Humans; Venous Thromboembolism | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Renal Insufficiency, Chronic; Venous Thromboembolism; Vitamin K | 2015 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
[The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Secondary Prevention; Stroke; Treatment Outcome | 2014 |
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2015 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2016 |
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K | 2018 |
52 trial(s) available for beta-alanine and dabigatran
| Article | Year |
|---|---|
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Electric Stimulation Therapy; Hemorrhage; Humans; Incidence; Retrospective Studies; Stroke; Warfarin | 2011 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Survival Analysis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Stroke; Warfarin | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Outcome | 2011 |
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Factors; Time Factors; Warfarin | 2011 |
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Topics: Adult; Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Cross-Over Studies; Dabigatran; Double-Blind Method; Endopeptidases; Factor Xa Inhibitors; Humans; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Young Adult | 2011 |
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
Topics: Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Computer Simulation; Dabigatran; Female; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Young Adult | 2012 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Warfarin | 2011 |
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Heart Arrest; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Single-Blind Method; Warfarin | 2012 |
The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Humans; Male; Middle Aged; Thrombin | 2012 |
[Expectation to and problems of thrombin inhibitor].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Radiography; Risk Factors; Warfarin | 2012 |
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Area Under Curve; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cross-Over Studies; Dabigatran; Factor VIIa; Humans; Kinetics; Male; Middle Aged; Morpholines; Prothrombin; Recombinant Proteins; Risk; Rivaroxaban; Thiophenes; Thrombin | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain Ischemia; Cardiac Pacing, Artificial; Cataract Extraction; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Risk Factors; Stroke; Thromboembolism; Warfarin | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Life Expectancy; Quality-Adjusted Life Years; Stroke; Sweden; Warfarin | 2013 |
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Perioperative Care; Thromboembolism; Warfarin | 2012 |
Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospitals, University; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2012 |
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dyspepsia; Female; Humans; Male; Middle Aged | 2013 |
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Perioperative Care; Premedication; Thrombosis; Treatment Outcome; Warfarin | 2013 |
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Thrombin; Warfarin | 2013 |
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Topics: Adult; Antithrombins; Benzimidazoles; Berlin; beta-Alanine; Blood Coagulation; Dabigatran; Drug Administration Schedule; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Regression Analysis; Renal Dialysis | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intention to Treat Analysis; International Normalized Ratio; Male; Middle Aged; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2013 |
Pharmacometric characterization of dabigatran hemodialysis.
Topics: Adult; Antithrombins; Benzimidazoles; beta-Alanine; Computer Simulation; Dabigatran; Forecasting; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Partial Thromboplastin Time; Predictive Value of Tests; Renal Dialysis | 2013 |
Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Prospective Studies; Quality of Life; Warfarin | 2013 |
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Cross-Sectional Studies; Dabigatran; Drug Monitoring; Female; Humans; Male; Mass Spectrometry; Middle Aged; Partial Thromboplastin Time; Prospective Studies; Prothrombin Time; Thrombin Time | 2013 |
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Postoperative Complications; Premedication; Risk Factors; Thromboembolism; Treatment Outcome; United States; Warfarin | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Stroke; Treatment Outcome | 2013 |
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Warfarin | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Stroke; Thromboembolism; Warfarin | 2013 |
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Warfarin | 2013 |
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Choice Behavior; Dabigatran; Decision Support Techniques; Female; Humans; Male; Middle Aged; Warfarin | 2013 |
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Glomerular Filtration Rate; Humans; Internationality; Kidney; Male; Middle Aged; Models, Biological; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult | 2014 |
Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Medication Adherence; Middle Aged; Treatment Outcome | 2014 |
Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies | 2014 |
Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Topics: Adult; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Point-of-Care Systems; Rivaroxaban; Thiophenes; Young Adult | 2014 |
Warfarin or dabigatran for treatment of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrhage; Humans; Software; Thromboembolism; Warfarin | 2014 |
An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis.
Topics: Administration, Oral; Adult; Aged; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Prodrugs; Pyridines; Renal Dialysis; Thrombin Time | 2014 |
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medical Records Systems, Computerized; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2014 |
[Re-allign (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis Implantation; Humans; Male; Metabolic Clearance Rate; Middle Aged; Thrombosis; Tissue Distribution; Treatment Outcome; Young Adult | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Dabigatran; Female; Hemoglobins; Humans; Incidence; Male; Middle Aged; Pacemaker, Artificial; Postoperative Hemorrhage; Prospective Studies; Warfarin | 2014 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
Idarucizumab for Dabigatran Reversal.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Thrombosis | 2015 |
620 other study(ies) available for beta-alanine and dabigatran
| Article | Year |
|---|---|
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.
Topics: Antithrombins; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Blood Platelets; Cell-Derived Microparticles; Dabigatran; Gene Expression; Humans; Leukocytes; Myocardial Infarction; Platelet Activation; Platelet Aggregation; RNA, Messenger; Thromboplastin | 2010 |
When a virtue becomes a problem. The new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Medication Adherence; Risk; Vitamin K; Warfarin | 2010 |
Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity.
Topics: Animals; Benzimidazoles; beta-Alanine; Dabigatran; Glucuronides; Humans; In Vitro Techniques; Macaca mulatta; Magnetic Resonance Spectroscopy; Microsomes | 2010 |
Dabigatran inhibits Staphylococcus aureus coagulase activity.
Topics: Benzimidazoles; beta-Alanine; Blood Coagulation; Coagulase; Dabigatran; Enzyme Inhibitors; Humans; Staphylococcus aureus | 2010 |
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Middle Aged; Recombinant Proteins; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2010 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Diagnosis, Differential; Dronedarone; Humans; Vitamin K | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Stroke; Warfarin | 2011 |
[Dabigatran induced exanthema].
Topics: Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Exanthema; Female; Humans | 2010 |
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Topics: Activated Protein C Resistance; Administration, Oral; Adult; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prothrombin Time; Reproducibility of Results; Thrombin | 2011 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin | 2010 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2011 |
The difference between Tdap and DTaP; dabigatran versus warfarin.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diphtheria-Tetanus-acellular Pertussis Vaccines; Humans; Product Surveillance, Postmarketing; Warfarin | 2011 |
Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Bleomycin; Dabigatran; Disease Models, Animal; Female; Lung Diseases, Interstitial; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Thrombin | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Topics: Advisory Committees; American Heart Association; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Randomized Controlled Trials as Topic; United States | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Fibrinolytic Agents; Humans | 2011 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Topics: Advisory Committees; American Heart Association; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Disease Management; Humans; Societies, Medical; United States | 2011 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Postoperative Complications; Randomized Controlled Trials as Topic; Venous Thromboembolism; Venous Thrombosis | 2011 |
[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Risk Assessment; Stroke; Vitamin K | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux.
Topics: Adenocarcinoma; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Resistance; Drug Therapy, Combination; Female; Fondaparinux; Humans; Middle Aged; Neoplasms, Unknown Primary; Polysaccharides; Syndrome; Treatment Outcome; Venous Thrombosis | 2011 |
Next generation anticoagulants may push warfarin to the wayside.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Evaluation; Humans; Medication Adherence; Stroke; Warfarin | 2011 |
New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug and Narcotic Control; Drug Approval; Humans; United States; United States Food and Drug Administration; Warfarin | 2011 |
Place of dabigatran in contemporary pharmacotherapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Female; Fracture Fixation; Hemiplegia; Hemorrhage; Humans; Ischemia; Postoperative Complications; Practice Guidelines as Topic; Prosthesis Failure; Risk; Stroke; Thrombolytic Therapy; Thrombosis | 2011 |
Differences between the varicella vaccines; using dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chickenpox Vaccine; Dabigatran; Half-Life; Herpes Zoster; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Preoperative Care | 2011 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Heart Rate; Humans; Stroke | 2011 |
Redemption by RE-DEEM?
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors | 2011 |
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease; Creatinine; Dabigatran; Fibrinolytic Agents; Glomerular Filtration Rate; Humans; Incidence; Kidney; Kidney Diseases; Morpholines; Netherlands; Patient Selection; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Decision Trees; Hemorrhage; Humans; Markov Chains; Risk Factors; Stroke; Warfarin | 2011 |
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabigatran; Humans; Male; Recurrence; Stroke; Ultrasonography; Warfarin | 2012 |
Dabigatran falsely elevates point of care international normalized ratio results.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; False Positive Reactions; Female; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Point-of-Care Systems; Thrombin | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Patient Education as Topic; Warfarin | 2011 |
Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Point-of-Care Systems; Pyridines; Reproducibility of Results; Unnecessary Procedures | 2011 |
Dabigatran in atrial fibrillation: pharmacology and clinical trials.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Thromboembolism; Treatment Outcome | 2011 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Electrocardiography; Heart Rate; Humans; Male; Outpatients; Stroke; Treatment Outcome | 2011 |
Dabigatran in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Practice Guidelines as Topic | 2011 |
[Is the era from the end of warfarin?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2011 |
New antithrombotic drugs and European approval processes.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Europe; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Dabigitran and the radiology department.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Humans; Radiology, Interventional; Thrombin | 2012 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
Drug-induced exanthem following dabigatran.
Topics: Adult; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Monitoring; Exanthema; Humans; Male; Thromboembolism; Treatment Outcome; Young Adult | 2011 |
The future of anticoagulant therapy.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Drug Approval; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
[New anticoagulants: "efficacy and safety" or "efficacy or safety"].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans | 2011 |
["Xa-tra-xa": opportunities and open questions about new anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Stroke; Warfarin | 2011 |
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
Topics: Aortic Valve; Aortic Valve Stenosis; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Resistance; Echocardiography, Transesophageal; Fibrinolytic Agents; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Intracranial Embolism; Male; Middle Aged; Postoperative Complications; Risk Adjustment; Severity of Illness Index; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Tolerance; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombin; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Topics: Antithrombins; Area Under Curve; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Dabigatran; Humans; Kidney Diseases; Models, Biological; Prodrugs; Pyridines | 2012 |
Dabigatran: will it change clinical practice?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Stroke; United States; Warfarin | 2011 |
Reversal of new oral anticoagulants.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2011 |
Update on dabigatran for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2011 |
What's a mother to do?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male | 2012 |
UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Chromatography, Reverse-Phase; Dabigatran; Drug Stability; Humans; Limit of Detection; Reference Standards; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thromboembolism | 2012 |
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Brain; Cerebral Hemorrhage; Dabigatran; Dose-Response Relationship, Drug; Mice | 2011 |
Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Humans; Injections, Intravenous; Risk Factors; Stroke; Tissue Plasminogen Activator | 2012 |
Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence.
Topics: Animals; Bacterial Adhesion; Benzimidazoles; beta-Alanine; Dabigatran; Enzyme-Linked Immunosorbent Assay; Fibrinogen; Immunohistochemistry; Mice; Placebos; Staphylococcus aureus; Thrombin; Virulence | 2011 |
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Cells; Cells, Cultured; Dabigatran; Drug Evaluation, Preclinical; Drug Interactions; HEK293 Cells; Heparin; Humans; Morpholines; Platelet Factor 4; Rivaroxaban; Sulfates; Thiophenes; Thrombocytopenia; Transfection | 2012 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Topics: Aged; Automation; Benzimidazoles; beta-Alanine; Biomarkers; Brain Ischemia; Calibration; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Radiography; Stroke; Thrombin | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Stroke; Warfarin | 2011 |
Dabigatran: a new oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Thromboembolism | 2011 |
Acutely injured patients on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Thrombelastography; Whole Blood Coagulation Time; Wounds and Injuries | 2011 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
[Anticoagulation in atrial fibrillation: a new era has begun].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Cerebrovascular Circulation; Dabigatran; Electric Countershock; Fatal Outcome; Fibrinolytic Agents; Humans; Male; Middle Aged; Stroke; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2011 |
Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs.
Topics: Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Fibrinolytic Agents; Humans; Male; Stroke; Tissue Plasminogen Activator | 2011 |
Using dabigatran in patients with stroke: a practical guide for clinicians.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Approval; Humans; Kidney; Liver; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; United States; United States Food and Drug Administration | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis; Warfarin | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Splenic Diseases | 2012 |
Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Artery Bypass; Dabigatran; Heparin; Humans; Male; Platelet Factor 4; Thrombocytopenia; Treatment Outcome | 2012 |
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Dabigatran; Drug Administration Schedule; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Thrombin | 2012 |
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Calibration; Dabigatran; Humans | 2012 |
Important data after drug approval: comment on "Dabigatran association with higher risk of acute coronary events".
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial Infarction; Thromboembolism | 2012 |
Dabigatran: do we have sufficient data?: comment on "Dabigatran association with higher risk of acute coronary events".
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial Infarction; Thromboembolism | 2012 |
Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial Hemorrhages; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Thrombin; Warfarin | 2012 |
Anticoagulant loses its lustre.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Stroke | 2012 |
Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Registries; Warfarin | 2012 |
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Feasibility Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Registries; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Interpretation of point-of-care INR results in patients treated with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Case-Control Studies; Dabigatran; Female; Humans; International Normalized Ratio; Male; Point-of-Care Systems | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Markov Chains; Models, Statistical; Monte Carlo Method; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
[New anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Countershock; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Risk Factors; Societies, Medical; Stroke; Ticlopidine; Vitamin K | 2012 |
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
Monitoring of the effects of new-generation oral anticoagulants – what does it mean? – .
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Partial Thromboplastin Time | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran (Pradaxa).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Thrombosis | 2012 |
Dabigatran product familiarisation programmes: who benefits, who shouldn't get it?
Topics: Aged, 80 and over; Anemia; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Product Surveillance, Postmarketing | 2012 |
Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Humans; Intracranial Hemorrhages; Patient Safety; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Electrocardiography; Embolism; Female; Follow-Up Studies; Heart Rate; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome; Warfarin | 2012 |
[Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments in favour of its utilisation as a first-choice drug].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial Embolism; Stroke | 2012 |
[Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments against its utilisation as a first-choice drug].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial Embolism; Stroke | 2012 |
Bleeding risk with dabigatran in the frail elderly.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Frail Elderly; Hemorrhage; Humans; Product Surveillance, Postmarketing; Risk | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2012 |
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.
Topics: Aged; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Factor VIIa; Humans; Male; Postoperative Hemorrhage; Recombinant Proteins; Renal Dialysis; Treatment Outcome | 2012 |
Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans; Hypotension; Respiratory Insufficiency; Severity of Illness Index | 2012 |
Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Hemorrhage, Traumatic; Brain Injuries; Dabigatran; Factor VII; Fatal Outcome; Glasgow Coma Scale; Humans; International Normalized Ratio; Male; Partial Thromboplastin Time; Subarachnoid Hemorrhage; Thrombin; Tomography, X-Ray Computed | 2012 |
Exfoliative esophagitis and esophageal ulcer induced by dabigatran.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Esophagitis; Esophagoscopy; Humans; Male; Ulcer | 2012 |
Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Platelets; Coagulase; Dabigatran; Fibrin; Hirudins; Humans; Integrin alpha2; Integrin beta3; Mutation; Platelet Aggregation; Platelet Function Tests; Receptors, IgG; Staphylococcus aureus; Thrombin; Time Factors; von Willebrand Factor | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Drug Interactions; Fibrinolytic Agents; Mice; Mice, Inbred C57BL; Stroke; Tissue Plasminogen Activator; Warfarin | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis.
Topics: Adult; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Humans; Intracranial Thrombosis; Magnetic Resonance Angiography; Male; Middle Aged; Off-Label Use; Phlebography; Treatment Outcome; Venous Thrombosis | 2012 |
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enzyme Inhibitors; Hep G2 Cells; Humans; K562 Cells; Mass Spectrometry; Models, Chemical; Protein Binding; Proteomics; Pyridines; Quinone Reductases; Thrombin | 2012 |
Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Renal Dialysis | 2012 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Hemorrhage; Humans; Patient Selection; Stroke; Warfarin | 2012 |
New medicines - urgent need to assess outcomes in special groups.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
Endovascular therapy after stroke in a patient treated with dabigatran.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheterization; Cerebral Angiography; Dabigatran; Endovascular Procedures; Female; Humans; Middle Cerebral Artery; Stroke; Tomography, X-Ray Computed | 2012 |
Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.
Topics: Atrial Fibrillation; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Premedication | 2012 |
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Female; Heart Valve Prosthesis; Hemorrhage; Male; Mitral Valve; Models, Animal; Sus scrofa; Thrombosis; Warfarin | 2012 |
Intravenous thrombolysis in a stroke patient taking dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Angiography; Dabigatran; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Platelet Count; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Assessment; Stroke; Thrombin; United States; United States Food and Drug Administration | 2012 |
Spontaneous ascending aortic intramural haematoma in a patient on dabigatran.
Topics: Administration, Oral; Aged; Anticoagulants; Aortic Diseases; Aortic Valve; Benzimidazoles; beta-Alanine; Blood Vessel Prosthesis Implantation; Chest Pain; Dabigatran; Dyspnea; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hematoma; Humans; Pericardial Effusion; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Drug Substitution; Factor Xa Inhibitors; Germany; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
An audience with... Gregory Lip. Interview by Asher Mullard.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Approval; Drug Industry; Humans; Registries; United States; United States Food and Drug Administration | 2012 |
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Narcotics; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Rivaroxaban; Thiophenes; Warfarin | 2012 |
An anticoagulation option for nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Humans; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Stroke; Warfarin | 2012 |
[Prevention of stroke in atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Rate; Humans; International Normalized Ratio; Intracranial Embolism; Myocardial Contraction; Risk Factors; Stroke; Thrombophilia | 2012 |
Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.
Topics: Angiography, Digital Subtraction; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Perfusion Imaging; Thrombin Time; Thrombolytic Therapy; Tissue Plasminogen Activator; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Prospective Studies; Stroke; Thromboembolism; Warfarin | 2012 |
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2012 |
Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Bone Neoplasms; Brain Ischemia; Comorbidity; Dabigatran; Hematuria; Humans; Kidney Failure, Chronic; Leuprolide; Male; Prostatic Neoplasms; Pulmonary Disease, Chronic Obstructive; Secondary Prevention; Thrombophilia; Urinary Retention | 2012 |
Dabigatran for stroke prevention in atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Stroke; Thrombosis; Treatment Outcome | 2012 |
Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2012 |
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Genotype; Humans; Stroke; Warfarin | 2012 |
Dabigatran: uncharted waters and potential harms.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pharmacovigilance; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Warfarin | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance.
Topics: Aged, 80 and over; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Epistaxis; Female; Humans; Metabolic Clearance Rate | 2012 |
Thrombotic events after discontinuing dabigatran: rebound or resumption?
Topics: Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Middle Aged; Recurrence; Thrombosis | 2012 |
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Colectomy; Combined Modality Therapy; Dabigatran; Emergencies; Erythrocyte Transfusion; Factor VIIa; Fatal Outcome; Female; Hemostatics; Humans; Kidney Diseases; Male; Plasma; Postoperative Hemorrhage; Recombinant Proteins; Renal Dialysis; Resuscitation; Thrombophilia | 2012 |
Can dabigatran be an alternative periprocedural anticoagulation for atrial fibrillation ablation?
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Perioperative Care; Thromboembolism | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
New anticoagulant fights for credibility.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Formularies as Topic; Humans | 2012 |
Fatal gastrointestinal hemorrhage after a single dose of dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Male | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Prescribing trends for dabigatran etexilate in primary care.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Ireland; Male; Off-Label Use; Postoperative Complications; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Stroke; Venous Thromboembolism | 2012 |
How country-specific should a country-specific cost-effectiveness analysis be?
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Warfarin | 2013 |
Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Combinations; Factor IX; Factor VII; Factor X; Female; Models, Animal; Placebos; Prothrombin; Rabbits | 2012 |
Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin | 2012 |
[The monitoring of application of dabigatran as a remedy of prevention of thromboembolic complications after hip joint arthroplasty].
Topics: Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Monitoring, Physiologic; Thromboembolism; Whole Blood Coagulation Time | 2012 |
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility Determination; Fees, Pharmaceutical; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Patient Preference; Patient Selection; Practice Patterns, Physicians'; Surveys and Questionnaires; United States; Warfarin | 2013 |
The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.
Topics: Animals; Antithrombins; Apolipoproteins E; Benzimidazoles; beta-Alanine; Blood Pressure; Body Weight; Collagen; Dabigatran; Endothelium, Vascular; Ethidium; Fluorescent Dyes; Heart Rate; Male; Mice; Mice, Knockout; Microscopy, Fluorescence; Oxidative Stress; Plaque, Atherosclerotic; Thrombin | 2012 |
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Survival Rate; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Body Mass Index; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Middle Aged; Obesity; Postoperative Complications; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.
Topics: Aged, 80 and over; Anemia; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dyspnea; Hemorrhage; Humans; Male; Pulmonary Alveoli; Pulmonary Fibrosis | 2013 |
In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Hemostasis; Humans; Middle Aged; Pipecolic Acids; Sulfonamides; Treatment Outcome | 2013 |
Dabigatran: rational dose individualisation and monitoring guidance is needed.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; New Zealand; Warfarin | 2012 |
Concerns about storage and application of dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Capsules; Dabigatran; Drug Packaging; Drug Stability; Drug Storage; Humans; Humidity; Morpholines; Rivaroxaban; Sunlight; Temperature; Thiophenes | 2013 |
Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Agranulocytosis; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Imidazoles | 2012 |
Fatality in a patient treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Humans; Shock, Hemorrhagic | 2013 |
Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran.
Topics: Acute Disease; Antithrombins; Benzimidazoles; beta-Alanine; Carpal Tunnel Syndrome; Dabigatran; Decompression, Surgical; Hematoma; Humans; Male; Middle Aged | 2012 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Stroke; Treatment Outcome; Warfarin | 2012 |
Safe use of hemodialysis for dabigatran removal before cardiac surgery.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Transplantation; Humans; Middle Aged; Renal Dialysis; Thrombin Time | 2012 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Evaluating and assessing dabigatran drug interactions.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Consultants; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Monitoring; Female; Humans; International Normalized Ratio; Middle Aged; Pharmaceutical Services; Pharmacists; Professional Role; Warfarin | 2012 |
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Male; Mice; Pyridines; Stroke; Treatment Outcome | 2012 |
Perioperative management of dabigatran: the Nelson experience to date.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Middle Aged; Postoperative Care; Preoperative Care; Surgical Procedures, Operative; Thromboembolism | 2012 |
Dabigatran: laboratory monitoring.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Costs; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Guideline Adherence; Health Care Surveys; Health Expenditures; Humans; Medical Audit; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Preventive Health Services; Thromboembolism; Time Factors; United States; Warfarin | 2012 |
Dabigatran in recurrent deep vein thrombosis: when one-size does not fit all.
Topics: Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Recurrence; Treatment Failure; Venous Thrombosis | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin | 2012 |
Dabigatran-induced acute hepatitis.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemical and Drug Induced Liver Injury; Chronic Disease; Dabigatran; Humans; Male | 2012 |
Hemorrhagic complications associated with dabigatran use.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male | 2012 |
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Risk Assessment; Rivaroxaban; Thiophenes | 2012 |
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2011 |
Diffuse alveolar hemorrhage associated with dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Lung Diseases; Male; Plasma; Radiography, Thoracic; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Male; Multiple Organ Failure; Partial Thromboplastin Time; Plasma; Shock, Hemorrhagic | 2012 |
Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Female; Heparin; Humans; Linear Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Risk Factors; Treatment Outcome; Warfarin | 2012 |
Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2012 |
The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Factors; Clinical Chemistry Tests; Dabigatran; Humans; Research Design | 2013 |
Mechanical valve thrombosis with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Echocardiography, Transesophageal; Female; Follow-Up Studies; Heart Diseases; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Middle Aged; Prosthesis Failure; Thrombosis | 2012 |
A 77-year-old man with a prolonged activated partial thromboplastin time.
Topics: Aged; Anticoagulants; Autoantibodies; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Factor VIII; Hemophilia A; Hemorrhage; Humans; Male; Partial Thromboplastin Time | 2012 |
Eligibility of patients with atrial fibrillation for new oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Retrospective Studies | 2013 |
Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Middle Aged; New Zealand | 2013 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
[Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Thromboembolism | 2012 |
Increase in referrals.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dental Service, Hospital; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Referral and Consultation; Rivaroxaban; Thiophenes; Tooth Extraction | 2012 |
[Role of new oral anticoagulants in interventional cardiology].
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cardiac Surgical Procedures; Cardiology; Dabigatran; Humans; Morpholines; Percutaneous Coronary Intervention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2012 |
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Europe; Humans; Postoperative Complications; Practice Guidelines as Topic; United States; Vascular Surgical Procedures; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hong Kong; Humans; Male; Quality of Life; Retrospective Studies; Stroke; Warfarin | 2012 |
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Monitoring, Intraoperative; Postoperative Hemorrhage; Reproducibility of Results; Sensitivity and Specificity | 2012 |
Editorial critique.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Wounds and Injuries | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium.
Topics: Action Potentials; Animals; Antithrombins; Atrial Function; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Electrophysiological Phenomena; Hemostatics; Male; Models, Animal; Nitric Oxide; Pulmonary Veins; Rabbits; Receptor, PAR-1; Thrombin | 2012 |
Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Endothelium, Vascular; Heparin; Humans; Thrombin | 2012 |
Periprocedural management and approach to bleeding in patients taking dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Half-Life; Hematemesis; Humans; Male; Melena; Plasma; Risk Factors; Stroke; Time Factors; Withholding Treatment | 2012 |
Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Gastrointestinal Hemorrhage; Half-Life; Hematocrit; Hemoglobins; Humans; Ibuprofen; Middle Aged; Plasmapheresis; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Respiration, Artificial | 2012 |
Public health. Change of heart.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Humans; Public Health; State Medicine; Stroke; United Kingdom | 2012 |
Case study. Risk and reward.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; England; Hospitals, Public; Organizational Case Studies; Patient Education as Topic; Risk Assessment | 2012 |
Fatal dabigatran toxicity secondary to acute renal failure.
Topics: Acute Kidney Injury; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Hematemesis; Humans; Male; Stomach Diseases | 2013 |
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Europe; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Patient Selection; Preventive Health Services; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Benefits of dabigatran maintained for more than two years.
Topics: American Heart Association; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain; Clinical Trials as Topic; Dabigatran; Humans; Risk Assessment; South Africa; Stroke; Time Factors; United States | 2012 |
[Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Humans; Intracranial Embolism; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
["That is going to be complicated." The difficulties of innovation].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diffusion of Innovation; Drug Discovery; Drug Industry; Humans | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Positive outcome after intentional overdose of dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Charcoal; Chelating Agents; Dabigatran; Drug Overdose; Emergency Service, Hospital; Female; Gastric Lavage; Humans; Middle Aged; Suicide, Attempted; Treatment Outcome | 2013 |
Removal of dabigatran by hemodialysis.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Overdose; Humans; Intracranial Hemorrhages; Male; Renal Dialysis | 2013 |
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Catheter Ablation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Electrocardiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Postoperative Care; Predictive Value of Tests; Preoperative Care; Reference Values; Risk Assessment; Severity of Illness Index; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Carboxylesterase; Chromatography, Liquid; Dabigatran; Humans; Plasma; Prodrugs; Pyridines; Rats; Tandem Mass Spectrometry | 2013 |
Iron complex, dabigatran and toxic epidermal necrolysis syndrome: a case-report.
Topics: Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Metalloproteins; Stevens-Johnson Syndrome; Succinates | 2013 |
Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Chemistry Tests; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Point-of-Care Systems; Pregnancy; Reproducibility of Results; Rivaroxaban; Thiophenes | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clopidogrel; Dabigatran; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
Topics: Aged; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Quality of Life; Quality-Adjusted Life Years; Stroke; Switzerland; Vitamin K | 2013 |
Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Care Surveys; Humans; Internet; Intracranial Hemorrhages; Partial Thromboplastin Time; Physicians; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; United States | 2013 |
Acute adrenal failure following anticoagulation with dabigatran after hip replacement and thrombolysis for massive pulmonary embolism.
Topics: Adrenal Gland Diseases; Adrenal Insufficiency; Aged; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pulmonary Embolism; Tissue Plasminogen Activator | 2013 |
When dabigatran and trauma collide.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle Aged; Wounds and Injuries | 2013 |
Australian MPs demand more data on dabigatran for atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; National Health Programs; Stroke | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Primary Prevention; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation; Dabigatran; Heparin; Hirudins; Humans; Peptide Fragments; Recombinant Proteins; Thrombelastography; Thrombin; Tissue Plasminogen Activator; Whole Blood Coagulation Time | 2013 |
Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Defibrillators, Implantable; Female; Humans; Male; Pacemaker, Artificial; Prospective Studies | 2013 |
[Wünderlich syndrome in patient anticoagulated with dabigatran].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Carcinoma, Transitional Cell; Dabigatran; Diabetes Mellitus, Type 2; Hematoma; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Nephrectomy; Pulmonary Disease, Chronic Obstructive; Retroperitoneal Space; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2013 |
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Topics: Administration, Oral; Analysis of Variance; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Humans; International Normalized Ratio; Laboratories; Morpholines; Partial Thromboplastin Time; Reproducibility of Results; Rivaroxaban; Thiophenes | 2013 |
Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Hyperkalemia; Kidney Transplantation; Male; Middle Aged; Renal Insufficiency, Chronic | 2013 |
Thrombolysis in ischemic stroke patients on treatment with Dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Humans; Stroke; Thrombolytic Therapy | 2013 |
Dabigatran elimination: is haemodialysis effective?
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Kidney Failure, Chronic; Male; Renal Dialysis | 2013 |
[Percutaneous left atrial appendage closure after resolution of left atrial appendage thrombi with dabigatran].
Topics: Anticoagulants; Antithrombins; Atherectomy; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Echocardiography, Transesophageal; Female; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Obesity, Morbid; Risk Factors; Stroke; Thrombosis; Treatment Outcome | 2013 |
[Dosage of the new oral anticoagulants is essential for frequency of adverse events].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans | 2013 |
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran].
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Electric Countershock; Humans; Ileus; Kidney Diseases; Male; Risk Factors; Thromboembolism; Tomography, X-Ray Computed; Vitamin K | 2013 |
[Dabigatran as cause of severe gastrointestinal bleeding in a Jehovah's Witness patient].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Critical Illness; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Jehovah's Witnesses; Plasma; Treatment Outcome; Treatment Refusal | 2013 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Extended treatment of venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2013 |
Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Platelet Aggregation Inhibitors; Telangiectasia, Hereditary Hemorrhagic; Warfarin | 2013 |
Dabigatran "non-inferior" to warfarin, but only just.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Pulmonary Embolism; Treatment Outcome; Venous Thrombosis; Warfarin | 2013 |
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate.
Topics: Benzimidazoles; beta-Alanine; Caffeic Acids; Dabigatran; Dose-Response Relationship, Drug; Drug Design; Fibrinolytic Agents; Humans; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Pyridines; Thrombin; Venous Thrombosis | 2013 |
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Antidotes edge closer to reversing effects of new blood thinners.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Humans; Pyrazoles; Pyridones; Recombinant Proteins; Vitamin K; Warfarin | 2013 |
Dabigatran overdose secondary to acute kidney injury and amiodarone use.
Topics: Acute Kidney Injury; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Drug Overdose; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Thrombin Time | 2013 |
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Catheter Ablation; Critical Illness; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Infusions, Intravenous; Intraoperative Complications; Male; Preoperative Care; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2013 |
A specific antidote for dabigatran: functional and structural characterization.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Dabigatran; Male; Mice; Mice, Inbred C57BL; Models, Biological; Models, Molecular; Rats; Rats, Wistar; Substrate Specificity | 2013 |
Monitoring the direct thrombin inhibitors.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 2013 |
Dabigatran and postmarketing reports of bleeding.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2013 |
Warfarin replacements: good for patients, challenging for laboratories.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Laboratories; Morpholines; Rivaroxaban; Thiophenes | 2013 |
[Aneurysm of abdominal aorta rupture in a patient on dabigatran treatment].
Topics: Aged; Antithrombins; Aortic Aneurysm, Abdominal; Aortic Rupture; Arrhythmias, Cardiac; Aspirin; Benzimidazoles; beta-Alanine; Blood Transfusion, Autologous; Clopidogrel; Dabigatran; Humans; Male; Plasma; Platelet Aggregation Inhibitors; Platelet Transfusion; Shock, Hemorrhagic; Ticlopidine | 2013 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Drug Utilization Review; Female; Health Expenditures; Hong Kong; Hospital Costs; Hospitals, Teaching; Humans; Male; Middle Aged; Preventive Health Services; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2013 |
DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report.
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Eruptions; Eosinophilia; Exanthema; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Humans; Intracranial Hemorrhages; Male; Recombinant Proteins; Thrombelastography; Thrombin | 2014 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Prospective Studies; Stroke; Warfarin | 2013 |
The role of staphylothrombin-mediated fibrin deposition in catheter-related Staphylococcus aureus infections.
Topics: Animals; Bacterial Adhesion; Bacterial Load; Benzimidazoles; beta-Alanine; Catheter-Related Infections; Central Venous Catheters; Coagulase; Dabigatran; Disease Models, Animal; Fibrin; Jugular Veins; Male; Mice; Mice, Inbred BALB C; Staphylococcal Infections; Thrombin | 2013 |
Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Mice; Prodrugs; Rabbits; Rats; RNA, Messenger; Thrombin; Thromboplastin; Thrombosis | 2013 |
Acute pulmonary emboli in a patient on long-term dabigatran therapy.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Pulmonary Embolism | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Female; Humans; International Normalized Ratio; Male; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; South Africa; Stroke; Warfarin | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Agents; Dabigatran; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome; Withholding Treatment | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Intraoperative Care; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Perioperative Care; Postoperative Complications; Prospective Studies; Registries; Risk Assessment; Severity of Illness Index; Survival Rate; Thromboembolism; Thrombolytic Therapy; Treatment Outcome; Warfarin | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Postoperative Complications; Pulmonary Veins; Warfarin | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Research Design; Stroke; Warfarin | 2013 |
Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Japan; Length of Stay; Male; Middle Aged; Premedication; Risk Factors; Thromboembolism; Treatment Outcome | 2013 |
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Lung Diseases; Male; Renal Dialysis; Treatment Outcome | 2013 |
A new oral anticoagulant in the setting of dermatologic surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Humans; Postoperative Complications; Thrombosis | 2013 |
Thrombolytic action of dabigatran in patients with acute pre-existing atrial thrombus.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transesophageal; Female; Heart Atria; Heart Diseases; Humans; Male; Thrombosis; Treatment Outcome | 2013 |
Severe necrotic oesophageal and gastric ulceration associated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Esophageal Diseases; Esophagoscopy; Gastroscopy; Humans; Male; Necrosis; Pneumonia, Aspiration; Stomach Ulcer; Tomography, X-Ray Computed; Vomiting | 2013 |
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Computer Simulation; Dabigatran; Decision Support Techniques; Decision Trees; Female; France; Health Services Research; Humans; Incidence; Male; Models, Statistical; Multivariate Analysis; Outcome and Process Assessment, Health Care; Prevalence; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood-Brain Barrier; Cerebral Arteries; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Humans; Ischemia; Mice; Mice, Inbred C57BL; Rats; Stroke; Thrombolytic Therapy; Warfarin | 2013 |
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Health Care Costs; Humans; Models, Economic; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Embolism; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Premedication; Retrospective Studies; Risk Assessment; Stroke; Tennessee; Treatment Outcome; Warfarin | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Dabigatran bleed risk with closed head injuries: are we prepared?
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage, Traumatic; Clinical Protocols; Craniocerebral Trauma; Dabigatran; Female; Humans; Male; Middle Aged; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Warfarin; Young Adult | 2013 |
Laboratory testing for the new oral anticoagulants: a review of current practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor X; Humans; Morpholines; Rivaroxaban; Surveys and Questionnaires; Thiophenes | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1 | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Blocking direct inhibitor bleeding.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Male | 2013 |
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Topics: Academic Medical Centers; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Substitution; Female; Humans; Male; Referral and Consultation; Stroke; United States; Warfarin | 2013 |
Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Warfarin | 2013 |
Haemodialysis before emergency surgery in a patient treated with dabigatran.
Topics: Ankle Injuries; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Medical Services; Female; Humans; Middle Aged; Nerve Block; Partial Thromboplastin Time; Preoperative Care; Renal Dialysis | 2013 |
Dabigatran in clinical practice--one-year experience at Skåne University Hospital.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Registries; Stroke; Sweden | 2013 |
Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG(®)) to guide decision-making.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Decision Making; Hematoma, Subdural; Humans; Thrombelastography | 2014 |
Can dabigatran improve blood pressure control?
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Hypertension; Losartan; Male | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Female; Hemorrhage; Humans; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Retrospective Studies; Risk Factors; Stroke | 2013 |
Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Echocardiography; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitral Valve Stenosis; Rheumatic Heart Disease; Thrombosis; Treatment Outcome; Warfarin | 2013 |
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Coronary Occlusion; Cost-Benefit Analysis; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Markov Chains; Models, Statistical; Ontario; Percutaneous Coronary Intervention; Quality-Adjusted Life Years; Risk Factors; Stroke; Warfarin | 2013 |
Placing a value on new technologies.
Topics: Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Occlusion; Dabigatran; Female; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Male; Percutaneous Coronary Intervention; Stroke; Transplantation; Warfarin | 2013 |
Dabigatran and bleeding: still an emergent situation?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Factor VIII; Hemorrhage; Humans; Prothrombin; Recombinant Proteins; Renal Dialysis | 2013 |
Dabigatran for left atrial thrombus.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Atria; Heart Diseases; Humans; Thrombosis | 2013 |
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2013 |
Dabigatran has the upper hand on warfarin.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Ischemia; Stroke; Thrombolytic Therapy | 2013 |
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Topics: Accidental Falls; Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Colonic Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Intestinal Perforation; Intestinal Volvulus; Leg Ulcer; Male; Renal Dialysis; Subarachnoid Hemorrhage | 2013 |
[New oral anticoagulants and digestive hemorrhages].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Brain Ischemia; Contraindications; Dabigatran; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Middle Aged; Partial Thromboplastin Time; Patient Selection; Predictive Value of Tests; Risk Assessment; Risk Factors; Stroke; Thrombin Time; Thrombolytic Therapy; Time Factors; Treatment Outcome | 2014 |
[Endovascular treatment of cerebral thrombosis in patient on dabigatran].
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Angiography; Contraindications; Dabigatran; Endovascular Procedures; Humans; Intracranial Thrombosis; Male; Thrombectomy; Thrombolytic Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Uncontrollable haemorrhage following dabigatran prophylaxis.
Topics: Abdomen; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Medical Services; Hemorrhage; Humans; Laparotomy; Male; Treatment Outcome | 2013 |
New oral anticoagulants in atrial fibrillation forever?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Stroke | 2013 |
Ischemic stroke in an obese patient receiving dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Middle Aged; Obesity; Proton Pump Inhibitors; Stroke | 2013 |
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Indicators and Reagents; Male; Middle Aged; Partial Thromboplastin Time; Thrombin; Thrombin Time | 2013 |
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Humans; Pyridines; Tandem Mass Spectrometry | 2013 |
Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care.
Topics: Adult; Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; California; Dabigatran; Female; Follow-Up Studies; Hospitals, Veterans; Humans; Male; Medication Adherence; Middle Aged; Pharmaceutical Services; Retrospective Studies; Stroke; Treatment Outcome | 2013 |
Dabigatran, electrical cardioversion and measuring the aPTT. A safety measure or an unnecessary assessment?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Female; Humans; Male; Partial Thromboplastin Time | 2013 |
Plasma dabigatran activity one week after discontinuation despite normal renal function.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Perioperative management of patients who are receiving a novel oral anticoagulant.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Thrombosis on a mechanical mitral valve anticoagulated with dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Humans; Male; Mitral Valve; Thrombosis | 2014 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Postoperative Complications; Thrombosis; Warfarin | 2013 |
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
"Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan.
Topics: Aged; Atrial Fibrillation; Attitude of Health Personnel; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Female; Government Agencies; Humans; Japan; Male; Middle Aged; Physicians; Safety | 2013 |
Dental management considerations for a patient taking dabigatran etexilate: a case report.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Oral Surgical Procedures | 2013 |
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Capsules; Chi-Square Distribution; Cross-Sectional Studies; Dabigatran; Dyspepsia; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Interviews as Topic; Male; Medication Adherence; Patient Education as Topic; Risk Factors; Stroke; Time Factors | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebrovascular Disorders; Clopidogrel; Comorbidity; Dabigatran; Drug Synergism; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Hypertrophy, Left Ventricular; Logistic Models; Male; Middle Aged; Models, Cardiovascular; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk; Ticlopidine; Treatment Outcome | 2013 |
Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Laparoscopy; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Robotics; Thrombosis | 2014 |
Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess.
Topics: Aged; Anti-Bacterial Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Decompression, Surgical; Epidural Abscess; Humans; Male; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Cord Compression; Treatment Outcome | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
RE-LYing on dabigatran for periprocedural anticoagulation: is it safe?
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Embolism; Intracranial Thrombosis; Male; Warfarin | 2013 |
[New anticoagulants, new emergencies?].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Warfarin | 2013 |
Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Heart Valve Prosthesis; Humans; Mitral Valve; Thromboembolism | 2013 |
Dabigatran monitoring made simple?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Calibration; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Partial Thromboplastin Time; Reference Values; Regression Analysis; Research Design; Risk; Thrombin; Time Factors | 2013 |
Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Device Removal; Drug Administration Schedule; Electric Countershock; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Prosthesis Implantation; Reoperation; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2013 |
Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Premedication; Risk Factors; Thromboembolism; Treatment Outcome | 2013 |
[New oral anticoagulants in nonvalvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2013 |
Rapid resolution of a spontaneous large chronic subdural haematoma in the posterior fossa under conservative treatment with platelet administration to aplastic anaemia.
Topics: Aged, 80 and over; Anemia, Aplastic; Anticoagulants; Benzimidazoles; beta-Alanine; Cranial Fossa, Posterior; Dabigatran; Female; Hematoma, Subdural, Chronic; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Thrombocytopenia; Tomography, X-Ray Computed | 2013 |
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; Hemorrhage; Humans; Male; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Thiophenes | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Anticoagulation-associated upper gastrointestinal haemorrhage.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Medical Audit; Upper Gastrointestinal Tract; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Contrast Media; Dabigatran; Iopamidol; Male; Mice; Radiography, Dual-Energy Scanned Projection; Time Factors; Warfarin | 2013 |
Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Angiography; Dabigatran; Endovascular Procedures; Female; Heart Failure; Humans; Paresis; Stroke; Thrombectomy; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2013 |
The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Incidence; Intracranial Embolism; Intracranial Thrombosis; Japan; Male; Middle Aged; Premedication; Prospective Studies; Risk Factors; Treatment Outcome; Warfarin | 2013 |
New oral anticoagulants and risks in ENT.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Otolaryngology; Rivaroxaban; Thiophenes | 2013 |
New oral anticoagulants in heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Failure; Humans; Male; Stroke; Warfarin | 2013 |
Reversal of a dabigatran overdose: what are possible options?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor VIIa; Hemorrhage; Humans; Prothrombin; Recombinant Proteins; Renal Dialysis | 2013 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assessment; Stroke; Thrombosis; Warfarin | 2013 |
Dabigatran and mechanical heart valves--not as easy as we hoped.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2013 |
Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Incidental Findings; Male; Predictive Value of Tests; Thrombolytic Therapy; Thrombosis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2014 |
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Hemorrhage; Kidney; Kidney Glomerulus; Male; Rats; Rats, Sprague-Dawley; Warfarin | 2014 |
Acute management of ST-elevation myocardial infarction patients taking dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2013 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Patient perspectives of dabigatran: analysis of online discussion forums.
Topics: Benzimidazoles; beta-Alanine; Consumer Health Information; Dabigatran; Drug Interactions; Fibrinolytic Agents; Food-Drug Interactions; Humans; Patient Safety; Perception; Social Media | 2014 |
Dabigatran-induced esophagitis.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Esophagitis; Esophagoscopy; Esophagus; Humans; Male | 2014 |
Fatal bleeding associated with dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Female; Hemorrhage; Humans | 2013 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
[Ischemic stroke after cardioversion and atrial flutter ablation in a patient taking dabigatran].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Cerebral Arteries; Dabigatran; Echocardiography; Electric Countershock; Humans; Male; Stroke | 2013 |
Acute kidney injury: renal hazards of anticoagulant therapy.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Rats; Warfarin | 2013 |
Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Fatal Outcome; Hematoma; Humans; Male; Risk Factors; Stroke; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Severe thrombosis of bioprosthesis mitral valve after dabigatran].
Topics: Adult; Antithrombins; Benzimidazoles; beta-Alanine; Bioprosthesis; Dabigatran; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Mitral Valve Insufficiency; Prosthesis-Related Infections; Thrombosis | 2013 |
Floating thrombus in the left upper pulmonary vein dissolved by dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Echocardiography, Transesophageal; Follow-Up Studies; Humans; Male; Multidetector Computed Tomography; Pulmonary Veins; Venous Thrombosis | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Warfarin | 2014 |
Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Dabigatran; Fat Emulsions, Intravenous; Hemorrhage; Male; Rats; Rats, Sprague-Dawley | 2013 |
Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Spain; Thiophenes | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
[New direct oral anticoagulants and venous thromboprophylaxis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Emergency Medical Services; Emergency Service, Hospital; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Male | 2013 |
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2014 |
Management of dabigatran-induced bleeding: expert statement.
Topics: Administration, Oral; Antithrombins; Austria; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Humans; Monitoring, Intraoperative; Postoperative Hemorrhage; Practice Guidelines as Topic; Thrombosis | 2013 |
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Diagnostic Tests, Routine; Drug Monitoring; Factor Xa Inhibitors; False Negative Reactions; Female; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Prothrombin; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombophilia | 2013 |
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Germany; Humans; Male; Models, Econometric; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Epistaxis; Female; Humans | 2014 |
Gastrointestinal bleeding associated with dabigatran in a patient with panhypopituitarism.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Embolism; Female; Gastrointestinal Hemorrhage; Humans; Hypopituitarism; Treatment Outcome | 2014 |
Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease.
Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Female; Gastrointestinal Hemorrhage; Glomerular Filtration Rate; Humans; Hypertension; Metabolic Clearance Rate; Renal Dialysis; Renal Insufficiency, Chronic; Thrombophilia; Urinary Tract Infections | 2013 |
Multiple data sources, the best way to gather safety information about medications.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic | 2014 |
Evaluation of pharmacist-managed dabigatran in an inpatient setting.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Pharmacists; Pharmacy Service, Hospital | 2013 |
Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation; Chromogenic Compounds; Dabigatran; Endopeptidases; Humans; Laboratory Proficiency Testing; Limit of Detection; Mass Spectrometry | 2013 |
Evaluation of dabigatran utilization and risk among hospitalized patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Dabigatran; Drug Interactions; Female; Humans; Inpatients; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2014 |
Acute ischemic stroke following cardioversion in a patient receiving dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Humans; Male; Stroke | 2013 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, Animal; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Rats; Rats, Wistar; Stroke; Tissue Plasminogen Activator; Warfarin | 2014 |
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Comorbidity; Dabigatran; Drug Dosage Calculations; Drug Substitution; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Education as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Registries; Risk Factors; Socioeconomic Factors; Stroke; Time Factors; Treatment Outcome; United States | 2013 |
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Stroke | 2013 |
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Topics: Amiodarone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; beta-Alanine; Clarithromycin; Dabigatran; Digoxin; Dronedarone; Drug Interactions; Humans; Models, Biological; Pyridines; Quinidine; Verapamil | 2014 |
[Prevention and treatment of major bleeding during anticoagulation].
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Diabetes Mellitus; Drug Therapy, Combination; Factor IX; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Risk Assessment; Risk Factors; Smoking; Vitamin K; Warfarin | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Evaluation of dabigatran exposures reported to poison control centers.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Child; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Poison Control Centers; Retrospective Studies | 2014 |
The antithrombotic effect of dabigatran.
Topics: Aged; Antithrombins; Atrial Appendage; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Echocardiography; Follow-Up Studies; Heart Diseases; Humans; Magnetic Resonance Imaging, Cine; Male; Multidetector Computed Tomography; Thrombosis | 2014 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Stroke; Survival Analysis; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. The authors' reply.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Warfarin | 2014 |
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
[Experience with rivaroxaban and dabigatran].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Morpholines; Protein C Deficiency; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment | 2014 |
Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Warfarin | 2014 |
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Diabetes Mellitus, Type 2; Drug Overdose; Hemorrhage; Humans; Hyperkalemia; Male; Neoplasms; Phlebitis; Renal Dialysis | 2014 |
Activated prothrombin complex concentrate for dabigatran-associated bleeding.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Female; Hematoma, Subdural; Hemorrhage; Humans; Male; Prothrombin; Tomography, X-Ray Computed | 2014 |
Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Dabigatran; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Massachusetts; Middle Aged; Retrospective Studies; Severity of Illness Index; Tertiary Care Centers; Treatment Outcome | 2014 |
How I treat target-specific oral anticoagulant-associated bleeding.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Factor VIIa; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Length of Stay; Male; Medical Audit; Middle Aged; Postoperative Care; Postoperative Hemorrhage; Prospective Studies; Venous Thromboembolism | 2014 |
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Brain Ischemia; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Partial Thromboplastin Time; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2014 |
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time | 2014 |
[New anticoagulants: stop or more?].
Topics: Adverse Drug Reaction Reporting Systems; Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Dissent and Disputes; Dose-Response Relationship, Drug; Drug Approval; Drug Industry; Drugs, Investigational; France; Humans; International Normalized Ratio; Lobbying; Pharmacovigilance; Thrombophilia | 2014 |
Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels.
Topics: Benzimidazoles; beta-Alanine; Blood Chemical Analysis; Dabigatran; Fibrinolytic Agents; Humans; Laboratories; Laboratory Proficiency Testing; Mass Spectrometry | 2014 |
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bone Marrow Transplantation; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Female; Immunoenzyme Techniques; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Receptor, PAR-1; Receptor, PAR-2; Rivaroxaban; Thiophenes; Thrombin; Vascular Diseases | 2014 |
Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Group Practice; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis | 2014 |
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
Topics: Animals; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Factor VIIa; Factor Xa Inhibitors; Immunoglobulin Fab Fragments; Liver; Pyridines; Recombinant Proteins; Swine; Thrombelastography | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Thrombin | 2014 |
Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Humans; Male | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Female; Hemorrhage; Humans; Kidney; Kidney Function Tests; Male; Renal Insufficiency; Stroke | 2014 |
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Warfarin | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Substitution; Early Termination of Clinical Trials; Female; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Middle Aged; Mitral Valve; Myocardial Infarction; Off-Label Use; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Vitamin K | 2014 |
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Brain; Brain Injuries; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Mice; Mice, Inbred C57BL; Warfarin | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Bronchial Arteries; Bronchiectasis; Dabigatran; Embolization, Therapeutic; Female; Hemoptysis; Humans; Infarction, Middle Cerebral Artery; Radiography | 2014 |
Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Male; Recurrence; Stroke | 2014 |
Dabigatran-induced lupus temporarily preventing blood group determination.
Topics: Aged, 80 and over; Anemia; Antibodies, Antinuclear; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Group Antigens; Dabigatran; Epistaxis; Female; Humans; Immunoglobulins; Lupus Erythematosus, Systemic | 2014 |
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Catheter Obstruction; Catheters; Dabigatran; Drug Dosage Calculations; Heart Valve Prosthesis Implantation; Heparin; Humans; In Vitro Techniques; Male; Models, Animal; Postoperative Complications; Rabbits; Thrombin; Thromboembolism; Thrombosis | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cross-Sectional Studies; Dabigatran; Fibrinolytic Agents; Humans; Registries; Stroke; Treatment Outcome | 2014 |
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Electric Countershock; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Response to "evaluation of dabigatran exposures reported to poison control centers".
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Poison Control Centers | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa.
Topics: Aged; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Dabigatran; Drainage; Factor VIIa; Head Injuries, Closed; Hematoma, Subdural; Humans; Hydrocephalus; Male; Partial Thromboplastin Time; Recombinant Proteins; Thrombin Time; Tomography, X-Ray Computed | 2014 |
Reply to comments on "evaluation of dabigatran exposures reported to poison centers".
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Poison Control Centers | 2014 |
Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Male | 2014 |
Chest pain caused by pulmonary vein thrombi could be curable by dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Chest Pain; Dabigatran; Humans; Male; Multidetector Computed Tomography; Pulmonary Veins; Venous Thrombosis | 2014 |
Dabigatran assessment in patients with acute complications using routine coagulation assays.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; United States; United States Food and Drug Administration; Warfarin | 2014 |
Early percutaneous pinning of hip fracture using propofol-ketamine-lidocaine admixture in a geriatric patient receiving dabigatran: a case report.
Topics: Aged, 80 and over; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, Local; Antithrombins; Benzimidazoles; beta-Alanine; Bone Nails; Dabigatran; Female; Femoral Neck Fractures; Humans; Ketamine; Lidocaine; Nurse Anesthetists; Propofol | 2014 |
Intracranial hemorrhage during dabigatran treatment.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male | 2014 |
Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Dabigatran; Humans; Mass Spectrometry; Molecular Structure; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Registries; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Heparin; Hirudins; Humans; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
A case of dabigatran-associated acute renal failure.
Topics: Acute Kidney Injury; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopsy; Dabigatran; Humans; Male; Renal Dialysis | 2013 |
[Hemodialysis to remove anticoagulant dabigatran during emergencies].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Diverticulitis; Emergencies; Humans; Male; Renal Dialysis | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
A new class of powerful and informative simultaneous confidence intervals.
Topics: Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biostatistics; Confidence Intervals; Dabigatran; Data Interpretation, Statistical; Humans; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
Enterococcus faecalis bacteremia and mitral valve endocarditis under dabigatran for stroke prevention.
Topics: Aged; Bacteremia; Benzimidazoles; beta-Alanine; Dabigatran; Endocarditis; Enterococcus faecalis; Fatal Outcome; Female; Gram-Positive Bacterial Infections; Heart Valve Diseases; Humans; Mitral Valve; Stroke | 2014 |
New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male | 2014 |
Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Female; Fetus; Humans; In Vitro Techniques; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Pyridines | 2014 |
Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes; Thrombin Time | 2014 |
γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Topics: Animals; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Carotid Arteries; Catalytic Domain; Cell Line; Cricetinae; Dabigatran; Humans; Mice; Mutation; Recombinant Proteins; Thrombin; Thrombin Time | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Middle Aged; Quality of Life; Ventricular Dysfunction, Left; Vitamin K | 2014 |
[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Urologic Surgical Procedures | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Coronary embolization following electrical cardioversion in a patient treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabigatran; Electric Countershock; Humans; Male; Radiography; Treatment Outcome | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Male; Middle Aged; Stroke; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2014 |
Dabigatran therapy: minor trauma injuries are no longer minor.
Topics: Accidental Falls; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hematoma; Hemostasis, Surgical; Humans; Leg Injuries; Subarachnoid Hemorrhage | 2014 |
The peri-procedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Retrospective Studies | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Retrospective Studies; Risk Factors; Stroke; Treatment Outcome; United States; United States Department of Veterans Affairs | 2014 |
[Two cases of dabigatran-induced esophageal ulcer indicating the usefulness of drug administration guidance].
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Esophageal Diseases; Female; Humans; Male; Ulcer | 2014 |
Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor Xa; Humans; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridones; Thrombelastography; Thrombin | 2014 |
Extensive dabigatran-induced exfoliative esophagitis harboring squamous cell carcinoma.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Carcinoma, Squamous Cell; Dabigatran; Endoscopy, Digestive System; Esophageal Neoplasms; Esophagitis; Female; Humans | 2014 |
An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; California; Child; Child, Preschool; Dabigatran; Drug Overdose; Female; Humans; Infant; Male; Middle Aged; Morpholines; Poison Control Centers; Prospective Studies; Retrospective Studies; Rivaroxaban; Thiophenes; Young Adult | 2014 |
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor VIIa; Hemorrhage; Humans | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospital Mortality; Humans; Intracranial Hemorrhages; Male; Odds Ratio; Retrospective Studies; Warfarin | 2014 |
Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Male; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Rabbits | 2015 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Insurance Claim Review; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk; Stroke; United States; Warfarin | 2014 |
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Dabigatran: how the drug company withheld important analyses.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Industry; Drug Monitoring; Europe; Hemorrhage; Humans; United States; United States Food and Drug Administration | 2014 |
The trouble with dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Monitoring; Hemorrhage; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2014 |
Concerns over data in key dabigatran trial.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Approval; Drug Industry; Drug Monitoring; Hemorrhage; Humans; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2014 |
Dabigatran, bleeding, and the regulators.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Monitoring; Europe; Hemorrhage; Humans; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Warfarin | 2014 |
[Vaginal bleeding as symptom of a medical emergency--pitfalls of therapy with new oral anticoagulants - case 5/2014].
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Emergencies; Female; Humans; Kidney Failure, Chronic; Metabolic Clearance Rate; Uterine Hemorrhage | 2014 |
Haemostasis. Part 2: Medications that affect haemostasis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Hematologic Agents; Hemostasis, Surgical; Heparin; Humans; International Normalized Ratio; Oral Hemorrhage; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Assessment; Warfarin | 2014 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Hong Kong; Humans; Male; Middle Aged; Risk Factors; Stroke; Treatment Outcome | 2014 |
Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran.
Topics: Aged, 80 and over; Angiography; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; Heart Diseases; Heart Ventricles; Humans; Male; Mesenteric Artery, Superior; Myocardial Infarction; Thromboembolism; Thrombosis; Tomography, X-Ray Computed | 2014 |
Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Prospective Studies; Sensitivity and Specificity | 2015 |
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Female; Follow-Up Studies; Humans; Incidence; Male; Medicare; Prognosis; Thromboembolism; Time Factors; United States | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Substitution; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; International Normalized Ratio; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Stroke; United States; United States Department of Veterans Affairs; Warfarin | 2014 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K | 2015 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Wandering pneumonia caused by dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Lung; Male; Pneumonia; Radiography; Remission, Spontaneous | 2014 |
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Stroke | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Topics: Alanine Transaminase; Animals; Benzimidazoles; beta-Alanine; Bile Acids and Salts; Dabigatran; Diet, High-Fat; Fatty Liver; Fibrin; Gene Expression; Inflammation; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thrombin; Weight Gain | 2014 |
Dabigatran: patient management in specific clinical settings.
Topics: Antithrombins; Arthroplasty, Replacement; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Practice Guidelines as Topic; Venous Thromboembolism | 2014 |
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Quality Control; Reference Values; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Topics: Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Thrombelastography; Young Adult | 2014 |
Dabigatran: gastrointestinal ulcers.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Diseases; Humans; Ulcer | 2014 |
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Tandem Mass Spectrometry | 2014 |
Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Calibration; Chromatography, High Pressure Liquid; Cold Temperature; Dabigatran; Drug Monitoring; Drug Stability; Factor Xa Inhibitors; Humans; Limit of Detection; Linear Models; Molecular Structure; Morpholines; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes; Time Factors | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Denmark; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Registries; Secondary Prevention; Stroke; Treatment Outcome; Warfarin | 2014 |
The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Carboxypeptidase B2; Dabigatran; Fibrinolysis; Humans; Pipecolic Acids; Protein C; Sulfonamides; Thrombin; Thrombomodulin | 2014 |
Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Poland; Practice Patterns, Physicians' | 2014 |
Laboratory monitoring of the non-vitamin K oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Surgical Procedures; Comparative Effectiveness Research; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Equipment Design; Female; Health Care Costs; Humans; Male; Markov Chains; Models, Economic; Models, Statistical; Probability; Quality-Adjusted Life Years; Stroke; Treatment Outcome; Uncertainty; Warfarin | 2014 |
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Hemorrhage; Hospitals, General; Humans; Italy; Male; Middle Aged; Retrospective Studies | 2014 |
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Belgium; Benzimidazoles; beta-Alanine; Biomarkers; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Equipment Design; Fibrinogen; Health Care Surveys; Humans; Laboratory Proficiency Testing; Morpholines; Observer Variation; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Quality Indicators, Health Care; Reproducibility of Results; Rivaroxaban; Thiophenes; Time Factors | 2015 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Male; Stroke; Tissue Plasminogen Activator | 2014 |
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Additional events in the RE-LY trial.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clopidogrel; Comorbidity; Dabigatran; Electric Countershock; Humans; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine | 2014 |
Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes | 2014 |
A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Retrospective Studies; Thromboembolism | 2014 |
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Humans; Thromboplastin; Warfarin | 2015 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
A modified prothrombin time to measure the anticoagulant activity of dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Prothrombin Time; Reproducibility of Results; Sensitivity and Specificity | 2014 |
Adverse skin reaction caused by dabigatran.
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Skin; Vasculitis, Leukocytoclastic, Cutaneous | 2014 |
Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty.
Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Body Fluids; Dabigatran; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Thromboembolism | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Kidney Diseases; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; Socioeconomic Factors; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
The importance of postapproval data for dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Risk of bleeding with dabigatran in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Incidence; Male; Medicare; Middle Aged; Retrospective Studies; Risk; United States; Warfarin | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Stroke; Warfarin | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; China; Cohort Studies; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Time Factors; Warfarin | 2015 |
Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Calibration; Chromatography, Liquid; Dabigatran; Dose-Response Relationship, Drug; Drug Labeling; Humans; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes; United States | 2015 |
Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Renal Dialysis | 2015 |
Bleeding and the new anticoagulants: strategies and concerns.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Hemostasis; Humans; Thrombin | 2015 |
Does dabigatran increase the risk of delayed hematoma expansion in a rat model of collagenase-induced intracerebral hemorrhage?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Collagenases; Dabigatran; Disease Models, Animal; Hematoma; Male; Rats; Rats, Wistar; Time Factors | 2015 |
Dabigatran-associated spontaneous acute cervical epidural hematoma.
Topics: Acute Disease; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Cervical Vertebrae; Dabigatran; Hematoma, Epidural, Spinal; Humans; Male; Prothrombin | 2015 |
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke; Young Adult | 2015 |
Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest.
Topics: Aged; Antithrombins; Aortic Aneurysm, Thoracic; Aortic Dissection; Benzimidazoles; beta-Alanine; Dabigatran; Hemostatic Techniques; Humans; Male; Postoperative Hemorrhage; Vascular Surgical Procedures | 2014 |
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Prothrombin; Reproducibility of Results; Risk Assessment; Russia; Stroke; Thromboembolism; Treatment Outcome | 2014 |
Urgent monitoring of dabigatran plasma levels: sometimes less is more.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans | 2014 |
Urgent monitoring of dabigatran plasma levels: sometimes less is more. Authors' reply.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans | 2014 |
New oral anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pilot Projects; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Hemorrhage; Hemostasis; Humans; Saphenous Vein; Thrombelastography; Thrombin | 2015 |
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
[Doubts about the new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Health Expenditures; Humans; Netherlands; Treatment Outcome | 2014 |
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Heparin; Humans; Lower Extremity; Male; Middle Aged; Severity of Illness Index; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Venous Thromboembolism; Warfarin | 2014 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2015 |
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Prevalence; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2014 |
[Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Warfarin | 2014 |
Case images: warfarin-induced skin necrosis: a 'novel' solution to an old problem.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Humans; Ischemic Attack, Transient; Male; Middle Aged; Necrosis; Skin; Skin Diseases; Thrombosis; Warfarin | 2014 |
Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Overdose; Humans; Male; Renal Dialysis | 2015 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
To monitor dabigatran or not: a matter of patient safety.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Patient Safety | 2015 |
Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Cerebral Hemorrhage; Dabigatran; Drug Monitoring; Fatal Outcome; Female; Half-Life; Hemorrhage; Humans; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Renal Replacement Therapy; Time Factors; Treatment Outcome | 2015 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Dabigatran abrogates brain endothelial cell permeability in response to thrombin.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain; Cell Survival; Cells, Cultured; Claudin-5; Dabigatran; Endothelial Cells; Glucose; Integrin beta1; Male; Mice; Mice, Inbred C57BL; Oxygen; Permeability; Thrombin | 2015 |
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2015 |
What is the role of hemodialysis for dabigatran-associated major bleeding?
Topics: Aged; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Observational Studies as Topic; Renal Dialysis | 2014 |
Patterns of oral anticoagulants use in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Drug Substitution; Drug Utilization Review; Female; Hospitals, University; Humans; Male; Practice Patterns, Physicians'; Quebec; Retrospective Studies; Stroke; Time Factors; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
[Triple anticoagulant therapy - now what can I give for pain?].
Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Contraindications; Dabigatran; Drug Therapy, Combination; Germany; Hemorrhage; Humans; Male; Risk Factors; Stents; Ticlopidine | 2015 |
[Antidote to dabigatran].
Topics: Antibodies, Monoclonal, Humanized; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Risk Factors; Thrombosis | 2015 |
Are new oral anticoagulant dosing recommendations optimal for all patients?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
[Exfoliative esophagitis while taking dabigatran].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy, Digestive System; Esophagitis; Female; Fluid Therapy; Humans; Hypertension; Pantoprazole | 2015 |
Site-level variation in and practices associated with dabigatran adherence.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Drug Monitoring; Female; Hospitals, Veterans; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Selection; Pharmacists; Retrospective Studies; United States | 2015 |
Ischemic stroke in patients on dabigatran: a role for rescue thrombectomy?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Thrombectomy; Thrombolytic Therapy | 2015 |
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Brain; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Hematoma; Mice; Thrombin Time; Warfarin | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Risk Factors; Thrombin Time | 2015 |
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombelastography; Venous Thromboembolism; Young Adult | 2015 |
Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro.
Topics: Antithrombins; Arrestins; Benzimidazoles; beta-Alanine; beta-Arrestins; Dabigatran; Gene Expression Regulation; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Protein Binding; Receptor, PAR-1; Signal Transduction; Thrombin | 2015 |
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Hong Kong; Humans; Incidence; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Perioperative Management of Dabigatran: A Prospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Disease Management; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Thromboembolism | 2015 |
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Treatment Outcome; Warfarin | 2015 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2015 |
[Advantages of NOAKs validated in clinical routine].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; General Practice; Humans; Stroke | 2015 |
Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Topics: Acute Disease; Aged; Benzimidazoles; beta-Alanine; Dabigatran; Decision Making; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Thrombin Time | 2015 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Minnesota; Mohs Surgery; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Skin Diseases; Thiophenes | 2015 |
Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Health Status Disparities; Humans; Japan; Male; Middle Aged; Neoplasms; Outpatients; Severity of Illness Index; Stroke; Treatment Outcome; Ultrasonography; Venous Thrombosis | 2015 |
Reversible Cognitive Impairment Associated with the Use of Dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cognition; Cognitive Dysfunction; Dabigatran; Follow-Up Studies; Humans; Male; Recovery of Function; Stroke | 2015 |
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Pulmonary Embolism; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thrombosis; Warfarin | 2015 |
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2015 |
Pharmacology: Dabigatran specific antidote.
Topics: Anticoagulants; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran | 2016 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban | 2017 |
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Dabigatran: Important Considerations in the Elderly.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans | 2017 |
Anticoagulation therapy: Uninterrupted dabigatran during ablation for AF.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Switching off the jitters: Dabigatran as a candidate approach to halt atrial fibrillation?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2018 |
Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Stroke; Warfarin | 2022 |